INTRODUCTION

1. This Survey reflects information provided by 56 industrial property offices and organizations on the grant and publication of SPCs.

2. A summary of the data contained in the Survey and examples of announcements regarding applications for SPCs and the grant thereof are given on pages following the replies to the last Question 12 and in the Appendices to the Survey.

3. For a definition of an SPC, please refer to the “Glossary of Terms Concerning Industrial Property Information and Documentation,” published in Volume IV, Part 10, of the WIPO Handbook on Industrial Property Information and Documentation CD-ROM.

4. The questionnaire submitted to industrial property offices for the preparation of this Survey contained the following questions:

QUESTIONS

1. Does your Office grant “supplementary protection certificates” or equivalent industrial property rights (SPCs) that extend the validity of patents covering medicinal, pharmaceutical, agrochemical or cognate products and phytopharmaceutical products? ...................................................2

2. Will your Office start granting SPCs in the future? .....................................................................................2

3. Please specify the legal basis for granting SPCs (national law, regional regulation, etc.). .......................3

4. Please give the name of the SPC granted by your Office..........................................................................5

5. Please specify for which fields of technology or which products an SPC can be obtained (for example, medicinal products, pharmaceutical products, phytopharmaceutical products, herbicides, agro-chemicals, all products subject to regulatory approval for marketing, etc.). ...................7

6. Does your Office publish or intend to publish the receipt of an application for an SPC? (If “Yes,” please attach specimen of a front page of an SPC and/or of announcements regarding SPCs made in an Official Gazette.) .................................................................8

7. If your reply to question 6 is “Yes,” please state the minimum elements that a publication must contain ........................................................................................................................................9

8. Does your Office publish or intend to publish the fact that an SPC has been granted? (If “Yes,” please attach specimen of a front page of an SPC and/or of announcement regarding the grant of SPCs made in an Official Gazette.) ..................................................................................13

9. If your reply to question 8 is “Yes,” please state the minimum elements that a publication must contain ........................................................................................................................................14

10. In what form does your Office make or intend to make the publications referred to in questions 6 and 8? ...........................................................................................................................................18

11. If your Office enters or intends to enter data from the documents relating to SPCs in online databases (internal or commercial), please give the name(s) of the database(s) and specify the bibliographic data elements: ........................................................................................................22

12. If your Office assigns or intends to assign specific application and/or registration numbers to SPCs, please give details. ........................................................................................................................................25
QUESTION 1:

Does your Office grant “supplementary protection certificates” or equivalent industrial property rights (SPCs) that extend the validity of patents covering medicinal, pharmaceutical, agrochemical or cognate products, and phytopharmaceutical products?

(a) In the field of medicinal products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US (24)

No: AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE (32)

Remarks:

MX: At the present time, there is no provision for the grant of SPCs in the Industrial Property Law, which has been in force since October 1, 1994. With regard to patents granted under the Law on the Development and Protection of Industrial Property, which was in force until September 1994, there is a provision for the grant of a three-year extension, provided that an exploitation license has been granted to a legal entity in majority Mexican ownership (Article 23 of the Law on the Development and Protection of Industrial Property).

UA: Although there is no SPC protection as such, an amendment to the Law of Ukraine on the Protection of Inventions and Utility Models provides for the extension of the term of patent protection for medicinal, animal or plant protection (phytopharmaceutical) products, the use of which is subject to an authorization issued by the competent authority. At the request of the patentee, the term of protection may be extended for the period that has elapsed from the filing of the application until the date of the authorization, up to a maximum of five years (Art. 6. of the amended Law referred to).

SI: The current legislation provides for an extension of not more than five years immediately on expiry of patents for which protection was sought on or after January 1, 1993.

(b) In the field of phytopharmaceutical products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US (24)

No: AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE (32)

Remarks:

KR: Phytopharmaceutical products are protected and treated in the same way as medicinal products.

SI: See explanation given in connection with question 1(a).

UA: See explanation given in connection with question 1(a).

QUESTION 2:

Will your Office start granting SPCs in the future?

(a) In the field of medicinal products

Yes: BG, HU, KZ, LT, SI, SK (6)

No: AP, BY, CA, CN, CU, EP, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE (17)

(b) In the field of phytopharmaceutical products

Yes: BG, HU, KZ, LT, SI, SK (6)

No: AP, CL, CN, CU, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE (15)
Remarks:
EP: With regard to the EPO, it should be noted that the grant and publication of SPCs for medicinal and for phytopharmaceutical products would be a matter for Contracting States under the European Patent Convention.
HU: Hungary will start granting SPCs in the field of medicinal and phytopharmaceutical products as from the date of accession to the European Union.
RO: New draft legislation is prepared for being considered by the Romanian Parliament in the future.
SI: New draft legislation is under consideration by the Slovenian Parliament.
SK: New draft legislation is under consideration by the Parliament of the Slovak Republic.

QUESTION 3:
Please specify the legal basis for granting SPCs (national law, regional regulation, etc.).

(a) In the field of medicinal products

AU: Australian Patents Act of 1990 (Sections 70 to 79 and Schedule 1); Australian Patents Regulations of 1991 (Regulation 6.7-6-11).
LV : Patent Law of 1995, Articles 7(9) and 31(5).
MD : Law No. 461-XIII, of May 18,1995, Art.20.1, on Patents for Invention of Supplementary Protection for pharmaceutical products, and Regulations under that law.
MX : Law on the Development and Protection of Industrial Property (Article 23), for patents granted under its provisions. SPCs are not granted under the legislation now in force (Industrial Property Law).

(b) In the field of phytopharmaceutical products

AU : Australian Patents Act of 1990 (Sections 70 to 79 and Schedule 1); Australian Patents Regulations of 1991 (Regulation 6.7-6-11).
LV: Patent Law of 1995, articles 7(9) and 31(5).
MD: Law No. 461/1995, on Patents for Invention of Supplementary Protection for pharmaceutical products.
NO: Act No. 9 of December 15, 1967, as amended by Act No. 40 of June 24, 1994, and No. 98 of December 19, 1997 (Chapter 9a, Section 62a) and 62b).

Remarks:
JP: Phytopharmaceutical products are protected and treated in the same way as medicinal products.

QUESTION 4:

Please give the name of the SPC granted by your Office.

(a) In the field of medicinal products

AT: Supplementary Protection Certificate (in German: “Ergänzendes Schutzzertifikat”).
AU: No special name given, merely a patent with an extended term of protection.
BE: Supplementary Protection Certificate for Medicinal Products (in French: “Certificat complémentaire de protection pour les médicaments”).
CY: Supplementary Protection Certificate for medicinal products.
DE: Supplementary Protection Certificate (in German: “Ergänzendes Schutzzertifikat”).
DK: Supplementary Protection Certificate for Medicinal Products (in Danish: “Supplerende beskyttelsescertifikat for laegemidler”).
EE: Supplementary Protection Certificate (in Estonian: “Täiendava Kaiste Tunnistus”).
GB: Supplementary Protection Certificate.
IE: Supplementary Protection Certificate.
IT: Supplementary Protection Certificate.
JP: No special name given (“Registration of extension of term of patent right”).
LU: Supplementary Protection Certificate for Medicinal Products.
LV : No special name given.
MD : Supplementary Protection Certificate.
MX : They have not been given any special name; a three-year extension of the validity of patents granted under the Law on the Development and Protection of Industrial Property (Article 23) is allowed. SPCs are not granted under the Industrial Property Law currently in force.
NO : Supplementary Protection Certificate (in Norwegian: “Supplerende beskyttelsessertifikat”).

(b) In the field of phytopharmaeaceutical products

AT : Supplementary Protection Certificate (“Ergänzendes Schutzzertifikat”).
AU : No special name given, merely a patent with an extended term of protection.
BE : Supplementary Protection Certificate for Phytopharmaeaceutical Products (in French: “Certificat complémentaire de protection pour les produits phytopharmaceutiques”).
CY : Supplementary Protection Certificate for Plant Protection Products (in Greek: “Συμπληρωματικό Πιστοποιητικό Προστασίας για Φυτοπροστατευτικά Προϊόντα”).
DE : Supplementary Protection Certificate (in German: “Ergänzendes Schutzzertifikat”).
EE : Supplementary Protection Certificate (in Estonian: “Täiendava Kaiste Tunnistus”).
GB : Supplementary Protection Certificate.
IE : Supplementary Protection Certificate.
IT : Supplementary Protection Certificate for Phytopharmaeaceutical Products.
JP : No special name given (“Registration of extension of term of patent right”).
LU : Supplementary Protection Certificate for Phytopharmaeaceutical Products.
LV : No special name given.
MD : Supplementary Protection Certificate.
NO : Supplementary Protection Certificate (in Norwegian: “Supplerende beskyttelsessertifikat”).
QUESTION 5:

Please specify for which fields of technology or which products an SPC can be obtained (for example, medicinal products, pharmaceutical products, phytopharmaceutical products, herbicides, agro-chemicals, all products subject to regulatory approval for marketing, etc.).

(a) In the field of medicinal products

AT : Medicinal products.
AU : Pharmaceutical products including phytopharmaceuticals.
BE : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
CH : Active ingredients or combinations of active ingredients of a medicinal product.
CY : Medicinal products only.
CZ : All medicinal products with marketing approval.
DK : Medicinal products.
EE : Medicinal products.
ES : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
FI : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
FR : Any product protected by a patent which has been granted marketing approval (applicable to medicinal and phytopharmaceutical products).
GB : Products placed on the market as medicinal products subject to authorization in accordance with Directives 65/65/EEC or 81/851/EEC.
IT : Medicinal products.
JP : Pharmaceutical products, pharmaceutical products for animals, agrochemicals and active ingredients.
KZ : All products for which marketing approval has been given.
LV : Medicinal or veterinary products covered by the provisions of laws in force on pharmaceuticals requiring obligatory testing and registration of the product prior to its being marketed in the Republic of Latvia.
MD : Medicinal products.
MX : Pharmaceutical products and processes and only for patents granted under the Law on the Development and Protection of Industrial Property. SPCs are not granted under the Industrial Property Law currently in force.
NL : Medicinal products subject to regulatory approval for marketing.
NO : Medicinal products and phytopharmaceutical products, including herbicides.
PT : Medicines.
SE : Medicinal products.
US : Human drugs, antibiotic drugs or human biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Public Health Services Act), new animal drugs or veterinary biological products(as those terms are used in the US Federal Food, Drug, and Cosmetic and the Virus-Serum-Toxin Act) which are not primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques, including any salt or ester of the active ingredient, as a single entity or in combination with another active ingredient, and any medical device, food additive, or color additive subject to regulation under the Federal Food, Drug, and Cosmetic Act.
(b) In the field of phytopharmaceutical products

AT: Plant protection products.
AU: Pharmaceutical products including phytopharmaceuticals.
BE: Phytopharmaceutical products as defined by Regulation (EC) No. 1610/96.
CH: Active ingredients or combinations of active ingredients of a phytopharmaceutical product.
CY: It covers all agricultural medicines including all plant protection products and herbicides.
CZ: All medicinal phytopharmaceutical products with marketing approval.
DK: Plant products.
EE: Plant protection products.
ES: Phytopharmaceutical products as defined by Regulation (EC) No. 1610/96.
FI: Plant products as defined in Regulation (EC) No. 1610/96.
FR: Any product protected by a patent that has been granted marketing approval (applicable to medicinal and phytopharmaceutical products).
GB: Products placed on the market as plant protection products subject to authorization in accordance with Article 4 of Directive 91/414/EEC.
IE: As defined in Regulation (EC) No. 1610/96.
IT: Phytopharmaceutical products.
JP: Drugs made from plants.
KZ: All products for which marketing approval has been given.
LU: Phytopharmaceutical products.
LV: Medicinal or veterinary products covered by the provisions of laws in force on pharmaceuticals requiring obligatory testing and registration of the product prior to its being marketed in the Republic of Latvia.
MD: Phytopharmaceutical products.
NL: Plant protection products subject to regulatory approval for marketing.
NO: Medicinal products and phytopharmaceutical products, including herbicides.
PT: Phytopharmaceutical products.
SE: Phytopharmaceutical products.
US: Human drugs, antibiotic drugs or human biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Public Health Services Act), new animal drugs or veterinary biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Virus-Serum-Toxin Act) which are not primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques, including any salt or ester of the active ingredient, as a single entity or in combination with another active ingredient, and any medical device, food additive, or color additive subject to regulation under the Federal Food, Drug, and Cosmetic Act.

QUESTION 6:

Does your Office publish or intend to publish the receipt of an application for an SPC? (If "Yes," please attach specimen of a front page of an SPC and/or of announcements regarding SPCs made in an Official Gazette.)

(a) In the field of medicinal products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, (25)
No: AP, CN, KZ, MX, MY, OA, US, (7)
Remarks:
BE: See Appendix 3.
CY: Intends to publish the receipts of SPC applications when its system is fully operational.
FI: For specimen announcements, see FIPO website www.prh.fi link “Patents” - in Patent Gazette under “Tehtyjä lisäsuojatodistushakemuksia-Ingivna ansökningar om tilläggsskydd”.
GB: See Appendix 11.
IT: The Office does publish the receipts of SPC applications.
LU: A notice is published either of the filing and refusal of an SPC application or of the filing and grant of an SPC.
MD: Data related to the filing or refusal of an SPC application are published.
PT: The application and mention of the grant.
RO: The Office intends to publish the receipts of SPC applications when the system will be operational.
US: However, the Food and Drug Administration publishes a determination related to the filing of an application for patent term extension, including the approval date of the product and the new drug application (or other application) number. See the attached Federal Register Notice (Appendix 21).

(b) In the field of phytopharmaceutical products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, RO, SE (24)
No: AP, CN, KZ, MX, MY, OA, US (7)

Remarks:
BE: See Appendix 3.
CY: Intends to publish the receipts of SPC applications when its system is fully operational.
GB: See Appendix 11.
JP: Phytopharmaceutical products are protected and treated in the same way as medicinal products.
MD: Data related to the filing or refusal of an SPC application are published.
PT: The application and mention of the grant.
RO: The Office intends to publish the receipt of SPC applications in the Bulletin when the system will be operational.
US: However, the Food and Drug Administration publishes a determination related to the filing of an application for patent term extension, including the approval date of the product and the new drug application (or other application) number. See the attached Federal Register Notice (Appendix 21).

(a) In the field of medicinal products

(i) Number assigned to receipt of the application

Yes: AT, AU, CH, CZ, BE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (23)
No: CY, DE (2)

Remarks:
AU: Application number is identical to patent number.
DE: See comment under question (viii).

(ii) Date of receipt

Yes: AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO (21)
No: AU, CY, DE, SE (4)
Remarks:

(iii) Name and address of the applicant
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

Remarks:
AU: Name but not address of applicant is published.

(iv) Number of the basic patent
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

(v) Title of the invention
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (22)
No: AU, JP, KR (3)

(vi) Number of any marketing authorization, including the product identified in the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (24)
No: AU (1)

Remarks:
AT: The Office publishes the date and number of the first authorization to market the product in Austria as a medicinal product and the date, country and number of the first such authorization in the EEA.
BE: The Office publishes data concerning the placing of the product on the market in Belgium.
CH: The Office publishes the number and date of the first authorization to market the product as a medicinal product in Switzerland and Liechtenstein.
DE: The Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.
ES: The number of the first authorization to market the product in Spain and in the European Union.
FI: The Office plans to publish data regarding the first authorization to market the product in Finland.
FR: The Office publishes the number and date of the first authorization to market the product in France as a medicinal product and number and date of the first authorization to market the product in the EEC as a medicinal product.
GB: The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the Community.
IE: Irish market authorization, and where relevant the number and date of the first authorization to market the product in the Community.
IT: The Office publishes the number and date of the first authorization to market the product in Italy as a medicinal product and number and date of the first authorization to market the product in the EEC as a medicinal product.
JP: In addition to the authorization and to the product identified therein, the Japanese Office gives information on the law under which the authorization was obtained, on the product and on the extent of its use.
LU: The Office publishes the number and date of the first authorization to market the product in Luxembourg as a medicinal product, and number and date of the first authorization to market the product in the EEC as a medicinal product.
NL: Number of the first relevant authorization in the Netherlands and, where different, the number of the first relevant authorization concerned in the EC.
NO: The Office intends to publish, where applicable, the number and date of the first authorization to market the product in the EEC.
(vii) Date of the authorization

**Yes:** AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, RO, SE (21).

**No:** AU, JP, KR, LV (4)

Remarks
- AT: See explanation given under question 7(a)(vi).
- FR: See explanation given under question 7(a)(vi).
- GB: See explanation given under question 7(a)(vi).
- IT: See explanation given under question 7(a)(vi).
- LU: The Office mentions the product as identified in the authorization to market the product in Luxembourg.
- NL: See explanation given under question 7(a)(vi).

(viii) Other elements (please specify)

**AT:** The publication contains also the following elements: the application number, the application date and date of grant of the basic patent, its IPC classification symbols, its language (if it is a European patent), the PCT application number (if applicable), the priority of the basic patent (if applicable) and the inventor's name (if applicable).

**BE:** Number and date of the first authorization to market the product in the EEC as a medicinal product.

**CH:** The Office also publishes a designation of the product covered by the authorization to market together with the name and address of the representative where applicable.

**CZ:** Product name.

**DE:** In addition to the minimum elements provided for in the ECC Regulation, the German Patent and Trademark Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.

**DK:** Including the EEA authorization (number and date) and the number in the Community Register of Medicinal Products.

**EE:** Identification data for the product specified in the authorization.

**ES:** Name of the product that has received the authorization.

**FI:** Name and address of the representative.

**FR:** Filing date, application number and date of grant of the basic patent.

**GB:** The product name.

**IE:** Where the authorization to market the product in Ireland is not the first authorization in the EEC, the number and date of that first authorization are also published.

**IT:** Name and address of the representative, filing date and date of grant.

**JP:** The Office publishes information regarding the extension of the term of protection of the patent.

**KR:** Claims relating to the product authorized. The product should also be identified in the claims.

**LU:** The Office names the product as identified in the authorization to market the product in Luxembourg.

**NL:** Name and address of the agent, if any, and name of the active ingredient as mentioned in the first relevant authorization in the Netherlands.

**SE:** Where relevant, the number and date of the first authorization to market the product in the EEC.

(b) In the field of phytopharmaceutical products

(i) Number assigned to receipt of the application

**Yes:** AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (22)

**No:** CY, DE (2)

Remarks:
- AU: Application number is identical to patent number.
- DE: See comment under question (viii).
(ii) Date of receipt
Yes: AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, PT, RO (20)
No: AU, CY, DE (3)

Remarks:
DE: See comment under question (viii).

(iii) Name and address of the applicant
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

Remarks:
AU: Name but not address of applicant is published.

(iv) Number of the basic patent
Yes: AT, AU, CH, CY, CZ, BE, DE, DK, EE, ES, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (24)

(v) Title of the invention
Yes: AT, CZ, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (23)
No: AU, JP, KR (3)

(vi) Number of any authorization to market the product, including the product identified in that authorization
Yes: AT, CZ, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)
No: AU (1)

Remarks:
AT: The Office publishes the date and number of the first authorization to market the product in Austria as a plant protection product and the date, country and number of the first such authorization in the EEA.
CH: The Office publishes the date and number of the first authorization to market the product as a phytopharmaceutical product in Switzerland and Liechtenstein.
DE: The German Patent and Trademark Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.
ES: The number of the first authorization to market the product in Spain and in the European Union.
GB: The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.
IE: Irish market authorization, and where relevant, the number and date of the first authorization to market the product in the Community.
JP: In addition to the authorization and to the product identified therein, the Japanese Office gives information on the law under which the authorization was obtained, on the product and on the extent of its use.
LU: The Office publishes the number and date of the first authorization to market the product in Luxembourg as a medicinal product, and number and date of the first authorization to market the product in the EEC as a medicinal product.
NL: Number of the first relevant authorization in the Netherlands and, where different, the number of the first relevant authorization in the EC.

(vii) Date of the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, RO, SE (21)
No: AU, JP, KR, LV (4)

Remarks:
AT: See explanation given under question 7(b) (vi).
DE: See explanation given under question (vi) above.
LU: The Office mentions the product as identified in the authorization to market the product in Luxembourg.

(viii) Other elements (please specify)
AT: See information given under question 7 (a) (vi).
BE: Number and date of the first authorization to market the product in the EEC as a phytopharmaceutical product.
CH: The Office also publishes a designation of the product covered by the authorization to market together with the name and address of the representative where applicable.
CZ: Product name.
DE: In addition to the minimum elements prescribed by the EEC Regulation, the German Patent Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.
DK: Including the EEA authorization (number and date) and the number in the Community Register of Medicinal Products.
EE: Identification data for the product specified in the authorization.
ES: Name of the product that has received the authorization.
FI: Name and address of the representative.
FR: Filing date, application number and date of grant of the basic patent.
GB: The product name.
IT: Name and address of the representative, filing date and date of grant.
KR: Claims relating to the product authorized. The product should also be identified in the claims.
LU: The Office mentions the product as identified in the authorization to market the product in Luxembourg.
NL: Name and address of the agent, if any, and name of the active ingredient as mentioned in the first relevant authorization in the Netherlands.
SE: Where relevant, the number and date of the first authorization to market the product in the EEC.

QUESTION 8:

Does your Office publish or intend to publish the fact that an SPC has been granted?
(If “Yes,” please attach specimen of a front page of an SPC and/or of announcement regarding the grant of SPCs made in an Official Gazette.)

(a) In the field of medicinal products
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)
No: MY, OM (2)

Remarks:
BE: See Appendix 3.
FI: For specimen announcement, see FIPO website www.prh.fi link “Patents”- in Patent Gazette under “Myönnetyjä lisäsuojatodistuksia- Bevilljade tilläggs skydd”.
GB: See Appendix 11.
MX: In the case of SPCs for patents granted under the old Law on the Development and Protection of Industrial Property the extension of validity is published in the journal “La Gaceta” (Article 8 of that Law).
RO: The Office intends to publish the grant of SPCs in the Bulletin when the system will be operational.
US: See sample of the Official Gazette notice attached to this Survey as Appendix 21.
(b) In the field of phytopharmaceutical products

Yes:  AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (26)

No:  MY, OM (2)

Remarks:
BE:  See Appendix 3.
DK:  Granted SPCs are not published.
GB:  See Appendix 11.
RO:  The Office intends to publish the grant of SPCs in the Bulletin when the system will be operational.
US:  See Appendix 21.

QUESTION 9:

If your reply to question 8 is "Yes," please state the minimum elements that a publication must contain

(a) In the field of medicinal products

(i) Registration number assigned to the granted SPC

Yes:  AT, AU, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, LU, LV, MD, NL, NO, PT, RO, SE, US (22)

No:  CY, DE, KR, US (4)

Remarks:
AU:  Application number is identical to patent number.
BE:  No special registration number is given; the number of the application for an SPC is used.
CH:  The Office uses the basic patent number with an addition ("CNNNNNN").
IE:  No special registration number is given; the number of the application for an SPC is used.
IT:  No special registration number is given; the number of the application for an SPC is used.
JP:  No special registration number is given; the patent number of the basic patent is used.
US:  No specific registration number is given; the publication number of the patent is used.

(ii) Date of the registration of the granted SPC

Yes:  AT, BE, CH, CZ, EE, ES, FR, GB, IE, IT, JP, KL, LV, MD, NO, PT, RO, SE, US (19)

No:  AU, CY, DE, DK, FI, KR, LU, NL (8)

Remarks:
AT:  The Office publishes the actual date of grant.
FR:  The Office specifies in its Official Gazette the expiry date of the SPC.
GB:  The Office publishes the actual date of grant, which is specified on the certificate.
IT:  The Office publishes the actual date of grant, which is specified on the certificate.
NL:  The Office publishes in the Official Gazette the date on which the SPC enters into force.

(iii) Name and address of the holder of the SPC

Yes:  AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (26)

No:  AU (1)

Remarks:
AU:  Name but not address of applicant is published.
US:  But the United States Patent and Trademark Office publishes the name only.

en / 07-07-01  Date:  January 2002
(iv) Number of the basic patent

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)

Remarks:
IT: Name and address of the representative, filing date and date of grant.

(v) Title of the invention

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (24)
No: AU, JP, KR (3)

(vi) Number of any marketing authorization, including the product identified in that authorization

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LV, MD, NL, NO, RO, SE (22)
No: AU, US (2)

Remarks:
AT: See explanations given under question 7(a)(vi).
CH: The Office publishes the number and date of the first authorization to market the product as a medicinal product in Switzerland and Liechtenstein.
DE: The German Patent and Trademark Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.
ES: The number of the first authorization to market the product in Spain and in the European Union.
FI: As in question 7(a)(vi).
FR: As in question 7(a)(vi).
GB: The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.
IE: Irish market authorization, and where relevant, the number and date of the first authorization to market the product in the Community.
IT: As in question 7(a)(vi).
JP: No special registration number is given; the patent number of the basic patent is used.
LU: As in question 7(a)(vi).
NL: Number of the first authorization in the Netherlands and, where different, the number of the first relevant authorization in the EC.
SE: As in question 7(a)(vi).

(vii) Date of the authorization

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (22)

(viii) Duration of the SPC

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, MD, NL, NO, PT, RO, US (23)
No: LV, SE (2)

Remarks:
AT: The duration is identified by the expiry date of the maximum period.
CH: The Office specifies the expiry date of the SPC.
ES: Expiry date of validity.
IE: The duration is identified by the expiry date of the maximum period.
LV: The duration is identified by the expiry date of the SPC.
(ix) Other elements, e.g. patent classification, product name (please specify)

AT: See explanations given under question 7(a) (viii).

CH: The Office also publishes a designation of the product covered by the authorization to market, the filing date of the application and the name and address of the representative where applicable.

CZ: Product name.

DE: In addition to the minimum elements prescribed by the EEC Regulation the German Patent and Trademark Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.

EE: Identification data for the product specified in the authorization.

ES: Name of the product that has received the authorization.

FI: Number and date of the corresponding application, name and address of the representative.

FR: Filing date, application number and date of grant of the basic patent.

GB: The product name.

IE: Where necessary, the fact that the application has been rejected is also published.

IT: Name and address of the representative, filing date and date of grant.

KR: Product name approved by authorization.

LV: Product name.

NL: Name and address of the agent, if any, and name of the product for which the SPC has been granted.

SE: Where relevant number and date of the first authorization to market the product in the EEC.

US: Patent grant date, applicant, owner of record, patent classification and product trade name.

(b) In the field of phytopharmaceutical products

(i) Registration number assigned to the granted SPC

Yes: AT, AU, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, LU, LV, NL, MD, NO, PT, RO, SE (22)

No: CY, DE, KR, US (4)

Remarks:

AU: Application number is identical to patent number.

BE: No special registration number is given; the number of the application for an SPC is used.

CH: The Office uses the basic patent number with an addition (“CNNNNNN”).

IE: No special registration number is given; the number of the application for an SPC is used.

JP: No special registration number is given; the number of the basic patent is used.

US: No specific registration number is given; the publication number of the patent is used.

(ii) Date of registration of the granted SPC

Yes: AT, BE, CH, CZ, EE, ES, FR, GB, IE, IT, JP, LV, MD, NO, PT, RO, US (17)

No: AU, CY, DE, DK, FI, KR, NL, SE (8)

Remarks:

AU: Name but not address of applicant is published.

US: But the United States Patent and Trademark Office publishes the name only.

(iii) Name and address of the holder of the SPC


No: AU (1)

Remarks:

AU: Name but not address of applicant is published.

US: But the United States Patent and Trademark Office publishes the name only.

(iv) Number of the basic patent

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (26)

Remarks:

IT: Name and address of the representative, filing date and date of grant.
(v) Title of the invention
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE, US (23)
No: AU, JP, KR (3)

(vi) Number of any market authorization, including the product identified in the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LV, MD, NL, NO, PT, RO, SE (23)
No: AU, US (2)

Remarks
AT: See explanations given under question 7(b)(vi).
CH: The Office publishes the number and date of the first authorization to market the product as a
phytopharmaceutical product in Switzerland and Liechtenstein.
DE: The German Patent and Trademark Office publishes the date and number of the first authorization
to market the product in Germany and, if different, the country, number and date of the first
authorization to market the product in the EEC.
ES: The number of the first authorization to market the product in Spain and in the European Union.
GB: The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and
where relevant, the number(s) and date(s) of the first authorization in the community.
IE: Irish market authorization, and where relevant, the number and date of the first authorization to
market the product in the Community.
JP: No special registration number is given; the number of the basic patent is used.
NL: The number of the first relevant authorization in the Netherlands and, where different, the number
of the first relevant authorization in the EC.

(vii) Date of the authorization
Yes: AT, BE, CH, CY, CZ, DE, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (21)

Remarks:
DE: See explanation given under question (vi) above.

(viii) Duration of the SPC
Yes: AT, AU, CH, CY, CZ, BE, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, MD, NL, NO, PT, RO, US (23)
No: LV, SE (2)

Remarks
AT: The duration is identified by the expiry date of the maximum period.
CH: The Office specifies the expiry date of the SPC.
ES: Expiry date of validity.
IE: The duration is identified by the expiry date of the maximum period.
LV: The duration is identified by the expiry date of the SPC.

(ix) Other elements, e.g. patent classification, product name (please specify)
AT: See information given under question 7(a)(viii).
CH: The Office also publishes a designation of the product covered by the authorization to market, the
filing date of the application and the name and address of the representative where applicable.
CZ: Product name.
DE: In addition to the minimum elements prescribed by the EEC Regulation, the German Patent and
Trademark Office publishes also the IPC main class symbol of the basic patent and the
application number of the SPC.
EE: Identification data for the product specified in the authorization.
ES: Name of the product that has received the authorization.

en / 07-07-01 Date: January 2002
FI : Number and date of the corresponding application, name and address of the representative.
FR : Filing date, application number and date of grant of the basic patent.
GB : The product name.
IE : Where necessary, the fact that the application has been rejected is also published.
IT : Name and address of the representative, filing date and date of grant.
KR : Product name approved by authorization.
LV : Product name.
NL : Name and address of the agent, if any, and name of the product for which the SPC has been granted.
SE : Where relevant, the number and date of the first authorization to market the product in the EEC.
US : Patent grant date, applicant, owner of record, patent classification, product trade name.

| QUESTION 10: |
| In what form does your Office make or intend to make the publications referred to in questions 6 and 8? |

(a) In the field of medicinal products
   (i) As regards applications for SPCs
      (a) As part of an Official Gazette?
         Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)
         No: US (1)
         Remarks:
         BE : Publication in the “Recueil des brevets d’invention” (monthly publication).
         CH : The Office also publishes a notice of SPC applications that have been refused.
         LU : Publication of a notice in the Official Gazette.
      (b) By publishing the application?
         Yes: AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, SE, US (24)
         Remarks:
         JP : Announcement is made in the Official Gazette.
      (c) By laying the application open to public inspection?
         Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (15)
         No: AT, AU, BE, DE, ES, JP, KR, LV, SE (9)
         Remarks:
         AU : The announcement in the Official Gazette states that the application is open to public inspection.
         CH : Only after notice of the application has been published.
         LU : The file may be consulted as from the date of grant (=publication date) of the SPC.
         NL : The application filed and correspondence between the Netherlands Industrial Property Office and the applicant are laid open to public inspection.
      (d) Through online databases (or the Office’s website)?
         Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, KR, NL (14)
         No: AU, EE, JP, LV, MD, NO, PT, SE, US (9)
Remarks:
AU: The internal database of the Office (PATADMIN) shows that an application has been made.
BE: Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
CH: All data on SPCs are contained in the internal BAGIS database and are accessible on the Office’s Website through the Online patentregister Swissreg after grant.
DE: Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
FI: The Patent Gazette is available on the FIPO website.
IE: Certain details are entered in the PTOLEMY database under the register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.

(e) By delivery of the copy application on request?
Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, KR, LU, MD, NL, PT, US (15)
No: AT, AU, BE, DE, ES, JP, LV, NO, SE (9)

Remarks:
CH: Reference is made to the comment under Question 10(a)(i)(c).
DE: Copies of SPC applications are available in the course of a file inspection.
KR: Copy delivery is possible for certain parts of the file that are available to the public.
US: Copies are provided upon payment of a fee.

(ii) As regards granted SPCs
(a) As part of an Official Gazette?
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)

Remarks:
BE: Publication in the “Recueil des brevets d’invention” (monthly publication).
LU: Publication of a notice in the Official Gazette.
MX: Only in the case of patents granted under the Law on the Development and Protection of Industrial Property.

(b) By publishing the SPC?
Yes: BE, US (2)
No: AT, AU, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, SE (22)

Remarks:
JP: Announcement is made in the Official Gazette.

(c) By laying the SPC open to public inspection?
Yes: BE, CH, CZ, DK, EE, FI, GB, IE, IT, LU, MD, NL, NO, PT, US (15)
No: AT, AU, DE, ES, FR, JP, KR, LV, SE (9)

Remarks:
BE: Consultation is possible for certain parts of the file that are available to the public.
LU: The file may be consulted as from the date of grant (= publication date) of the SPC.
NL: The application as filed, correspondence exchanged between the Netherlands Industrial Property Office and the applicant, and the granted SPC are laid open to public inspection.

(d) Through online databases (or the Office’s website)?
Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, LV, NL, US (15)
No: AU, JP, MD, NO, PT, SE (6)
Remarks:
AU: The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.
BE: Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
CH: All data on SPCs are contained in the internal BAGIS database and are accessible on the Office’s Website through the Online patentregister Swissreg after grant.
DE: Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
FI: The Patent Gazette is available on the FIPO website.
IE: Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.
US: SPC and Official Gazette Notice are available on USPTO’s website.

(e) By delivery of a copy of the SPC on request?
Yes: AT, BE, CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, PT, US (16)
No: AU, DE, ES, JP, LV, NO, SE (7)

Remarks:
AT: Copy delivery is possible for certain parts of the file that are available to the public.
BE: Copy delivery is possible for certain parts of the file that are available to the public.
DE: Copies of SPC files are available in the course of a file inspection.

(b) In the field of phytopharmaceutical products

(i) As regards applications for SPCs

(a) As part of an Official Gazette?
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)
No: US (1)

Remarks:
BE: Publication in the “Recueil des brevets d’inventin” (monthly publication).
CH: The Office also published a notice of SPC applications that have been refused.
LU: Publication of a notice in the Official Gazette.

(b) By publishing the application?
Yes: JP (1)
No: AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, KR, LU, LV, MD, NL, NO, PT, SE, US (23)

Remarks:
JP: Announcement is made in the Official Gazette.

(c) By laying the application open to public inspection?
Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (15)
No: AT, AU, BE, DE, ES, JP, KR, LV, SE (9)

Remarks:
AU: The announcement in the Official Gazette states that the application is open to public inspection.
LU: The file may be consulted as from the date of grant (= publication date) of the SPC.
NL: The application as filed and correspondence exchanged between the Netherlands Industrial Property Office and the applicant are laid open to public inspection.
(d) Through online databases (or the Office’s website)?

Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, KR, NL (14)
No: AU, EE, JP, LV, MD, NO, PT, SE, US (9)

Remarks:
AU: The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.
BE: Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
CH: All data on SPCs are contained in the internal BAGIS database and are accessible on the Office’s Website through the Online Patentregister Swissreg after grant.
DE: Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
FI: The Patent Gazette is available on the FIPOI website.
IE: Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—The Register entry is viewable on the public search system of the Office.

(e) By delivery a copy of the application on request?

Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, KR, LU, MD, NL, PT, US (15)
No: AT, AU, BE, DE, ES, JP, LV, NO, SE (9)

Remarks:
CH: Reference is made to the comment under Question 10(a)(i)(c).
DE: Copies of SPC applications are available in the course of a file inspection.
KR: Copy delivery is possible for certain parts of the file that are available to the public.
US: Copies are provided upon payment of a fee.

(ii) As regards granted SPCs

(a) As part of an Official Gazette?


Remarks:
BE: Publication in the “Recueil des brevets d’invention” (monthly publication).
CH: The Office also publishes a notice of SPC applications that have been refused.
LU: Publication of a notice in the Official Gazette.

(b) By publishing the SPC?

Yes: BE, JP, US (3)
No: AT, AU, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, KR, LU, LV, MD, NL, NO, PT, SE (21)

Remarks:
JP: Announcement is made in the Official Gazette.

(c) By laying the SPC open to public inspection?

Yes: BE, CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (16)

Remarks:
BE: Consultation is possible for certain parts of the file that are available to the public.
LU: The file may be consulted as from the date of grant (=publication date) of the SPC.
NL: The application as filed, the correspondence between the Netherlands Industrial Property Office and the applicant, and the granted SPC are laid open to public inspection.
(d) Through online databases (or the Office’s website)?
   Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, NL, US (14)
   No: AU, EE, JP, LV, MD, NO, PT, SE (8)

Remarks:
AU: The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.
BE: Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
CH: All data on SPCs are contained in the internal BAGIS database and are accessible on the Office’s Website through the Online Patentregister Swissreg after grant.
DE: Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
FI: The Patent Gazette is available on the FIPO website.
IE: Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.
US: SPC and Official Gazette Notice are available on USPTO’s Website.

(e) By delivery of a copy of the SPC on request?
   Yes: AT, BE, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, PT, US (15)
   No: AU, DE, ES, JP, LV, NO, SE (7)

Remarks:
BE: Copy delivery is possible for certain parts of the file that are available to the public.
CH: Reference is made to the comment under Question 10(a)(i)(c).
DE: Copies of SPC files are available in the course of a file inspection.

QUESTION 11:

If your Office enters or intends to enter data from the documents relating to SPCs in online databases (internal or commercial), please give the name(s) of the database(s) and specify the bibliographic data elements:

(a) In the field of medicinal products
   (i) Name(s) of database(s)
      AT: The Office’s SPC Register (“Schutzzertifikatsregister”) contains all data elements specified under question 9.
      AU: PATADMIN (internal database).
      CH: BAGIS (internal database only); Swissreg (Online Patent Register on Office’s Website); INPADOC (commercial).
      CY: Not yet available.
      CZ: Czech Patent Database (Internet).
      DE: (i) Patent Register, (ii) PATDPA (via STN International).
      DK: INPADOC.
      ES: SIDATEX.
      FI: INPADOC.
      FR: (i) RSPAT, (ii) EPAT.
      GB: RSPC, this is the internal database for SPCs which has been made available on the Patent Office website: http://webdb2.patents.gov.uk/rspc/.
      IE: (i) PTOLEMY (internal database), (ii) PTOLEMY Public Search System.
      IT: The Office has only an internal line, with the bibliographic data elements mentioned in paragraph (ii) below.
      JP: Data are included in an internal database (no name given).
MD : Patent Database.
NL : Computerized Register (in Dutch: "Het Octrooiregister") to be found on the website of the Netherlands Industrial Property Office.
RO : Data will be included in an internal database.

(ii) Bibliographic data elements
AT : The Office’s SPC Register ("Schutzzertifatsregister") contains all data elements specified under question 9.
AU : Application number, serial number, extension status, date of lodgment of extension application, market authorization date, extended expiry date, date of acceptance of extension, date of grant of extension, date of refusal of extension, date of withdrawal of extension, dates of advertisement of lodgment, acceptance, grant, withdrawal and refusal of the application for extension, date of filing of opposition, service address.
CH : Application number of SPC, application number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
CZ : See information given under questions 7 and 9.
DE : Application number of SPC, application number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
ES : See information given under questions 7 and 9.
FR : Same data as those published in the Official Gazette.
GB : See Appendix 11, pages 1 and 2, from the Patents and Designs Journal.
IE : • Application number- identical to the grant publication number;
• whether application is for medicinal or plant protection patent;
• date of application;
• date of publication of application;
• name and address of applicant;
• basic patent;
• date of expiry of patent;
• title of patent;
• Irish market authorization number, date of grant, identity of product authorized, legal provision of authorization;
• community market authorization, country, date of grant, identity of product authorized, legal provision of the authorization;
• product identity;
• address for service;
• application status;
• date of grant;
• date of publication of grant;
• renewal fees.
IT : • Application number-identical to the grant publication number;
• filing date;
• owner;
• representative;
• date of grant;
• product (name);
• references of the basic patent;
  ◦ title;
  ◦ application date;
  ◦ grant date;
  ◦ publication number;
  ◦ Italian AMM (marketing authorization): number, date of grant;
  ◦ community AMM: country, number, date of grant;
  ◦ status (active, idle, withdrawn);
  ◦ dates: - of entry into force;
        - of protection period.
### In the field of phytopharmaceutical products

#### (i) Name(s) of database(s)

<table>
<thead>
<tr>
<th>Country</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>The Office’s SPC Register (“Schutzsertifikatsregister”) contains all data elements specified under question 9.</td>
</tr>
<tr>
<td>AU</td>
<td>PATADMIN (internal database).</td>
</tr>
<tr>
<td>CH</td>
<td>BAGIS (internal database only); Swissreg (Online Patent Register on Office’s Website); INPADOC (commercial).</td>
</tr>
<tr>
<td>CY</td>
<td>Not yet available.</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Patent Database (Internet).</td>
</tr>
<tr>
<td>DE</td>
<td>(i) Patent Register, (ii) PATDPA (via STN International).</td>
</tr>
<tr>
<td>DK</td>
<td>INPADOC.</td>
</tr>
<tr>
<td>ES</td>
<td>SIDATEX.</td>
</tr>
<tr>
<td>FI</td>
<td>INPADOC.</td>
</tr>
<tr>
<td>FR</td>
<td>(i) FPAT, (ii) EPAT.</td>
</tr>
<tr>
<td>GB</td>
<td>RSPC, this is the internal database for SPCs which has been made available on the Patent Office website: <a href="http://www.webdb2.patents.gov.uk/rspc">http://www.webdb2.patents.gov.uk/rspc</a>.</td>
</tr>
<tr>
<td>IE</td>
<td>See answer to Question 11(a)(i).</td>
</tr>
<tr>
<td>JP</td>
<td>Data are included in an internal database (no name given).</td>
</tr>
<tr>
<td>KR</td>
<td>KIPO Patent Term Extension Database.</td>
</tr>
<tr>
<td>MD</td>
<td>Patent Database.</td>
</tr>
<tr>
<td>NL</td>
<td>Computerized Register (in Dutch: “Het Octrooiregister”) to be found on the website of the Netherlands Industrial Property Office.</td>
</tr>
<tr>
<td>RO</td>
<td>Data will be included in an internal database.</td>
</tr>
</tbody>
</table>

#### (ii) Bibliographic data elements

<table>
<thead>
<tr>
<th>Country</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>The Office’s SPC Register (“Schutzsertifikatsregister”) contains all data elements specified under question 9.</td>
</tr>
<tr>
<td>AU</td>
<td>Application number, serial number, extension status, date of lodgment of extension application, market authorization date, extended expiry date, date of acceptance of extension, date of grant of extension, date of refusal of extension, date of withdrawal of extension, dates of advertisement of lodgment, acceptance, grant, withdrawal and refusal of the application for extension, date of filing of opposition, service address.</td>
</tr>
<tr>
<td>CH</td>
<td>Application number of SPC, application number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.</td>
</tr>
<tr>
<td>CZ</td>
<td>See information given under questions 7 and 9.</td>
</tr>
<tr>
<td>DE</td>
<td>Application number of SPC, application number of basic patent, title of the invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.</td>
</tr>
<tr>
<td>ES</td>
<td>See information given under questions 7 and 9.</td>
</tr>
<tr>
<td>FR</td>
<td>Same data as those published in the Official Gazette.</td>
</tr>
<tr>
<td>GB</td>
<td>See Appendix 11, pages 1 and 2, from the Patents and Designs Journal.</td>
</tr>
<tr>
<td>IE</td>
<td>See answer to Question 11(a)(ii).</td>
</tr>
</tbody>
</table>
QUESTION 12:

If your Office assigns or intends to assign specific application and/or registration numbers to SPCs, please give details.

(a) In the field of medicinal products

(i) Concerning the numbering system for applications for SPCs

AT: The application number and the registration number are prefixed with “SZ” followed by a serial number, which restart at 1 every year, and the four-digit number of the year (SZ NNNN/YYYY).

AU: No specific numbering system is applied (see replies to questions 7 and 9).

BE: Before 2000: 09Y C XXXX, since 2000: 2xxxC/XXX.

CH: The Office uses the basic patent number with an addition (“CNNNNNN”).

CZ: An annual number series for SPC applications is applied. Example: SPC/CZYYYY/1.

DE: A certain range of numbers within the series of patent application numbers is used for SPC applications.

DK: CA YYYY XXXXXX.

EE: C YYYY NNNN (where C denotes the SPC; YYYY the year and NNN the number of the SPC application of the year).

ES: CYYYYNINNN.

FI: Annual number series in format: L CCYY NNNN, e.g. L 2000 0001.

FR: AACXXXX (where AA is the year of filing of the application, C is for an SPC (type of title) and XXXX the registration number). Example: 97C0019 means the 19th SPC filed in 1997; no distinction is made between a medicinal and a phytopharmaceutical product.

GB: SPCs are identified SPC/GB/, followed by the two-digit year and the case number. The case numbers are ordered chronologically by the application date, beginning with 001 for the first application of the calendar year, e.g. SPC/GB/99/001 was the first application received in 1999; no distinction is made between medicinal and phytopharmaceutical products.

IE: The Office uses the format SPC YYYYNNNN, where YYYY represents the year in which the application is filed and NNN is the application number, commencing with 001 for the first application filed in a given year.

IT: The Office uses the following format for SPC application numbers: UBYYCCPN. The first two digits are the abbreviation of “Ufficio Brevetti,” the next two (YY) denote the filing year of the SPC application, the letters CCP the type of industrial property title, and N the serial number of the SPC application in ascending order, starting with 1.

JP: The Office uses an annual numbering series for SPC applications consisting of a numeral to identify the year of filing (by year of the reign of the Emperor until 1999) followed by a six digit number starting with 700 001.

KR: No specific numbering system is applied. The application number of patent is used.

LU: Upwards series; as SPCs are entered in the Patent Register, the numbering system for patents is used.

MD: C YYYY NNNN.

NL:

- From 1993 to 1999, the number system was YY0NNNN, where YY are the last two digits of the year of filing, 0 is the numeral zero and NNN is a serial number from 001 onwards.
- Since 2000, a serial numbering system beginning with 300 001.

NO: SPC/NO YYYY NNN, where YYYY is the year and NNN is a three digit number (e.g. SPC/NO 2000 001).
SE : A special number is given to an SPC consisting of seven digits and a check digit. The first two digits indicate the last two digits of the year, the digit 9 indicates the SPC, and the four digits indicate a serial number. For example, 0090004-3 is the fourth SPC application in the year 2000, and 3 is the check digit.

US : Publication number of patent is used.

(ii) Concerning the numbering system for registrations or grants of SPCs (if different from (a)(i))

BE : The application number is used.
CH : The Office uses the basic patent number with an addition (“CNNNNNN”).
CY : It is planned as follows: CY/year/001.
DE : The number of the granted SPC is identical to the number of the application for an SPC.
DK : CR YYYY XXXXXX.
FI : Serial number in grant order.
GB : There is no change to the application number to signify that the application has been granted.
IE : The granted SPC retains the application number given.
IT : The number of the granted SPC is identical to the number of the applications for an SPC.
JP : No specific number is given. The granted SPC takes to the patent number.
MD : The number of the granted SPC is identical to the number of the applications for an SPC.

(b) In the field of phytopharmaceutical products

(i) Concerning the numbering system for applications for SPCs

AT : The application number and the registration number are prefixed with “SZ” followed by a serial number, which restart at 1 every year and the four digit number of the year (SZ NNNN/YYYY).
AU : No specific numbering system is applied (see replies to Questions 7 and 9).
BE : Before 2000: 09Y C XXXX, since 2000: 2xxxC/XXX.
CH : The Office uses the basic patent number with an addition (“CNNNNNN”).
CZ : An annual number series for SPC applications is applied. Example: SPC/CZYYYY/1.
DE : The same numbering system as for SPCs for medicinal products is used.
DK : CA YYYY XXXXXX.
EE : C YYYY NNNN (where C denotes the SPC, YYYY the year and NNN the number of the SPC application of the year).
ES : CYYYYNNNN.
FI : Annual number series in format K CCYY NNNN, e.g. K 1998 0004.
FR : AACXXXX (where AA is the year of filing of the application, C is for an SPC (type of title) and XXXX the registration number). Example: 97C0019 means the 19th SPC filed 1997; no distinction is made between a medicinal and a phytopharmaceutical product.
GB : SPC’s are identified SPC/GB, followed by the two digit year and the case number. The case numbers are ordered chronologically by the application date beginning with 001 for the first application of the calendar year, e.g., SPC/GB 99/001 was the first application received in 1999; no distinction is made between medicinal and phytopharmaceutical products.
IE : The Office uses the format SPC YYYYNNN, where YYYY represents the year in which the application is filed and NNN is the application number, commencing with 001 for the first application filed in a given year.
IT : See answer given to question 12(a)(i).
JP : The Office uses an annual numbering series for SPC applications consisting of a numeral to identify the year of filing (by year of the reign of the Emperor until 1999) followed by a six-digit number starting with 700 001.
KR : No specific numbering system is applied. The application number of patent is used.
MD : C YYYY NNNN.
NL : • From 1997 to 1999, the number system was YY1NNN, where YY are the last two digits of the year of filing, 1 is the numeral one and NNN is a serial number from 001 onwards.
  • Since 2000, a serial numbering system beginning with 350 001.
NO : SPC/NO YYYY NNN, where YYYY id the year and NNN is a three-digit number (e.g. SPC/NO 2000 001).
A special number is given to an SPC consisting of seven digits and a check digit. The first two digits indicate the last two digits of the year, the digit 9 indicates the SPC, and the four digits indicate a serial number. For example, 0090004-3 is the fourth SPC application in the year 2000, and 3 is the check digit.

US : Publication number of patent is used.

(ii) Concerning the numbering system for registrations or grants of SPCs (if different from (b)(i))

BE : The application number is used.

CH : The Office uses the basic patent number with an addition ("CNNNNNN").

CY : It is planned as follows: CY/Year/001.

DE : The number of the granted SPC is identical to the number of the application for a SPC.

DK : CR YYYY XXXXXX.

FI : Serial number in grant order.

GB : There is no change to the application number to signify that the application has been granted.

IE : The granted SPC retains the application number given.

IT : See answer given to Question 12(a)(ii).

MD : The number of the granted SPC is identical to the number of the application for an SPC.

Remarks:

EE : The numbering of SPC grants will be different from that of SPC applications (no SPC has been granted so far).

IE : See Appendix 12.

JP : No specific number is given. The granted SPC takes the patent number.

[Summary follows]
SUMMARY

1. With regard to the grant of SPCs, in the field of medicinal products as well as phytopharmaceutical products, the replies show that:
   - 24 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US) grant SPCs in the field of medicinal products and in the field of phytopharmaceutical products, whereas two Offices (UA, SI) provide, in a particular manner, protection derived from some general national legislation;
   - 32 offices (AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE) do not yet grant SPCs, although six of them (BG, HU, KZ, LT, SI, SK) intend to grant SPCs in the field of medicinal products and in the field of phytopharmaceutical products;
   - 18 Offices (AP, BY, CA, CL, CN, CU, EP, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE) do not intend, at least in the near future, to grant SPCs in the field of medicinal products and 15 of those (AP, CL, CN, CU, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE), in the field of phytopharmaceutical products.

2. As to the publication of applications for SPCs,
   - 25 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE), in the field of medicinal products, and 24 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, RO, SE), in the field of phytopharmaceutical products, publish or intend to publish in their Official Gazettes, whereas
   - seven Offices (AP, CN, KZ, MX, MY, OA, US) do not intend to do so either for medicinal or for phytopharmaceutical products.

3. As regards the grant of SPCs,
   - 26 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US) publish or intend to publish grants in their Official Gazettes.

4. Several Offices enter bibliographic data of the documents relating to SPCs in internal or commercial databases (see replies to Question 11).

5. 22 Offices (AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, MD, NL, NO, SE, US) gave information on the numbering system that they used for SPC applications or grants in the field of medicinal products and phytopharmaceutical products. The following formats (or examples) were given by the Offices:

   (i) for applications for SPCs,
   - SZ NNNN/YYYY (used by AT for applications and grants); before 2000: YYYYCNNNN; since 2000: YYYYC/NNN (used by BE for applications and grants);,
   - CNNNNNN (used by CH for applications and grants);
   - SPC/CZYYYY/1 (used by CZ);
   - CA CCYY XXXXXX (used by DK);
   - C YYYY NNNN (used by EE);
   - L YYYY NNNN (used by FI for medicinal products)
     K YYYY NNNN (used by FI for phytopharmaceutical products);
   - YYYYCNNNN (used by FR for applications and grants);,
   - SPC/GBYYYY/NNN (used by GB for applications and grants);
   - SPC YYYYNNNN (used by IE for applications and grants);
• UBYYCCPN (used by IT for applications and grants);
• YYYY – 700 001 (used by JP)\(^{(1)}\);
• (Year of the reign of the Emperor) – 700 001 (used by JP until 1999)\(^{(1)}\);
• C YYYY NNNN (used by MD for applications and grants);
• 300 001 (used by NL for applications and grants of medicinal products since 2000)\(^{(2)}\)
  350 001 (used by NL for applications and grants of phytopharmaceutical products since 2000)\(^{(2)}\)
• YY0NNN (used by NL for applications and grants of medicinal products from 1993 to 1999)\(^{(2)}\)
• YY1NNN (used by NL for applications and grants of phytopharmaceutical products from 1997 to 1999)\(^{(2)}\);
• SPC/NO YYYY NNN (used by NO for applications and grants);
• YY9NNNN-D (used by SE for applications and grants)\(^{(2)}\);

(ii) for registrations or grants of SPCs,
• CY/YYYY/NNN (planned by CY);
• CR CCYY NNNNN (used by DK).

6. Examples of announcements concerning SPC applications and SPC grants published by several Offices (AT, AU, BE, CH, CZ, DE, DK, EE, ES, FR, GB, IE, IT, JP, LU, LV, NL, NO, PT, SE, US) are reproduced as Appendices 1 to 21 to this Survey.

\(^{(1)}\) Note regarding the format used by BE, EE and FR. The letter “C” contained in the number series denotes the kind of industrial property right, namely, the SPC (CCP in French)

\(^{(2)}\) See reply to question 12
APPENDIX 1

AT

Österreichisches Patentamt
92, qg./Nr. 11
November 1995


Patentschriften – Schutzschriften

Seite 2958

<table>
<thead>
<tr>
<th>Patentnummer</th>
<th>Klasse</th>
<th>Anmelder</th>
<th>Art.</th>
<th>Erteilungsdatum</th>
<th>Erteilungsdatum</th>
<th>Anmelder</th>
<th>Staat</th>
</tr>
</thead>
</table>

Die folgenden Erteilungen betreffen Erfindungen auf dem Gebiet des Umweltschutzes bzw. Energiesparen (01). Nachstehende (02) sind ausführliche Informationen und sind bei den Erteilungsdaten enthalten.

<table>
<thead>
<tr>
<th>Patentnummer</th>
<th>Anmelder</th>
<th>Staat</th>
</tr>
</thead>
<tbody>
<tr>
<td>P010 0112</td>
<td>Figgis, J.</td>
<td>D-80319 München</td>
</tr>
<tr>
<td>P011 0113</td>
<td>Figgis, J.</td>
<td>D-80319 München</td>
</tr>
</tbody>
</table>

AUSGEBEBENE PATENTSCHEPFERN

Die Verkaufsrechte der Patentbeträgen sind in Druckschriften der Verkauf der nachstehenden Patentbeträgen mit und ohne Bestellung durch das Patentamt Mündung in eine staatliche Gewerbezählstelle und bei der Vereinigung von Mündung bis Freistellung von der UHR bis UHR.)

PREIS DER PATENTSCHEPFERN: 80 00 JETZT

Am 25. 10. 1985 sind die nachstehenden Patentschriften ausgebessere: WORRER

<table>
<thead>
<tr>
<th>Patentnummer</th>
<th>Anmelder</th>
<th>Staat</th>
</tr>
</thead>
<tbody>
<tr>
<td>001 0114</td>
<td>Figgis, J.</td>
<td>D-80319 München</td>
</tr>
</tbody>
</table>

SCHRIFTZERTIFIKATE

AL ERGEBNISSE ANZEIGEN:

<table>
<thead>
<tr>
<th>Patentnummer</th>
<th>Anmelder</th>
<th>Staat</th>
</tr>
</thead>
<tbody>
<tr>
<td>P012 0115</td>
<td>Figgis, J.</td>
<td>D-80319 München</td>
</tr>
</tbody>
</table>

GEBRANDE: (AT) 1987-02-30 1-19834

Gebrauch: (EWR) 1988-11-27 DK 8425

en / 07-07-01 Date: January 2002
AT

Österreichisches Patentblatt
52. Jg./Nr. 11
November 1995

Schutzverfahren

Genanntziffern (AT): 1995 03 09 1-288026
Genanntziffern (EWP): 1994 03 23 08 1059200055

Handbuch on industrial property information and documentation

Ref.: Examples and IPO practices

Appendix 1, page 2
APPENDIX 2

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

Alteration of Name in Register – cont’d

676810 ABB K.K. The name of the patentee(s) has been changed to ABB Alstom Power K.K.

694008 Courtaulds Aerospace, Inc. The name of the patentee(s) has been changed to FRC-DeSoto International, Inc.

694281 The Cronos Group Société Anonyme The name of the patentee(s) has been changed to The Cronos Group S.A.

694376 Courtaulds Aerospace, Inc. The name of the patentee(s) has been changed to FRC-DeSoto International, Inc.

696472 Brettos Limited The name of the patentee(s) has been changed to Brettos Pty Limited

Extensions of Term, Standard Patent – cont’d

566881 Glaxo Group Ltd.

ZINNAT (Cefuroxime) as axetil (amorphous)

Date extended term due to expire on 21/07/2007

578703 BYK Gulden Lomberg Chemische Fabrik GmbH

SOMAC (pantoprazole)

Date extended term due to expire on 23/01/2010

591066 Novartis AG and Henkel Kommanditgesellschaft Auf Aktien
disodium pamidronate in crystalline pentahydrate form

Date extended term due to expire on 05/08/2010

594082 Glaxo Group Ltd.

ZINNAT (Cefuroxime as axetil)

Date extended term due to expire on 21/07/2007

595192 Galderma Research & Development

Differin Topical Gel adapalene

Date extended term due to expire on 29/11/2010

599988 Pharmacia & Upjohn AB

Entring (estradiol/coestradiol) Vaginal Ring

Date extended term due to expire on 25/10/2011

627456 Schering Aktiengesellschaft

LEVOVIST

Date extended term due to expire on 04/07/2011

530251 Boehringer Ingelheim Pharmaceuticals Inc. and Dr Karl Thomas GmbH

Nevirapine ("Viramune")

Date extended term due to expire on 07/05/2012

635401 Novartis AG and University College London

SIMULECT basiliximab

Date extended term due to expire on 18/02/2014

636330 Glaxo Wellcome Inc.
AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

13 January 2000

Opposition under Section 104(4) – Withdrawn
63514 Monsanto Company (Zeneca Limited)

Application Withdrawn
69450 ANI Corporation Limited. The (BHP Steel (RP) Pty Ltd)

Letters Patent Sealed

Patent Patents

The following Patent Specification(s) were sealed and notified as open to public inspection on the date shown above the numbers.

Notices under the provision of Section 28(1) S 888(10) may be lodged at the Patent Office within the prescribed time.

13 Jan 2000
52695/99 714830 35091/99 714859
18275/99 714940 23845/99 714941
53633/99 715006 33978/99 715009
58347/99 715045 47401/99 715102
17386/99 715106

Offer To Surrender Patent

It is hereby notified that Buono-Net Australia Pty Limited, Unit 3 10 Richmond Road, Homebush, NSW 2140 Australia, the Patentee of Patent No 698985 dated 12 February 1998 for an invention titled ‘Body washer and exfoliant’ offers to surrender the said Patent Patent Any person desiring to be heard before the said offer of surrender is accepted must lodge a request to be heard within one month from the date of this journal.

It is hereby notified that Firebelt Pty Limited, 10–12 Pacific Highway, Caringbah, NSW 2229 Australia, the Patentee of Patent No 667454 dated 21 March 1998 for an invention titled ‘A vehicle refuse bin combination’ offers to surrender the said Patent Any person desiring to be heard before the said offer of surrender is accepted must lodge a request to be heard within one month from the date of this journal.

Proceedings Under Section 215

Amendment under Section 215, death of the applicant

Application 65779/98
The Applicant, Garry S. Lineseth has deceased. Irene A. Lineseth, personal representative of the estate has been recorded as the applicant.

Assignments Registered
579285 Paul Samani. The patent has been assigned to New Dimensions (Aust) Pty Ltd

Extensions of Term of Standard Patents, Section 70

Application accepted

Notice of opposition under Section 78(1) to the undermentioned application(s) for an extension of term may be lodged at the Patent Office within the prescribed time.

644939 Merck Sharp & Dohme Ltd.
MAXALT (rizatriptan benzoate)
Address for Service: SPRUSON & FERGUSON GPO Box 3888 SYDNEY NSW 2001

Date extended term due to expire on 08/06/2014

Grant

The following application(s) for Extension of Term have been granted under Section 74.

526270 Akzo Nobel N.V.

Vecuronium Bromide (C34H57BrN2O4)

Date extended term due to expire on 28/02/2001

529263 Dalichi Pharmaceutical Co., Ltd

Offensin (C18H23OF2N3O4)

Date extended term due to expire on 02/09/2006

529215 Merck and Co. Inc.

PRlMAXIN (limipanem + cilastatin sodium)

Date extended term due to expire on 23/02/2002

529265 Schering A.G.

Ultravist

Date extended term due to expire on 07/03/2005

530380 Merck and Co. Inc.

RElITIC enalaprilmleate)

Date extended term due to expire on 16/04/2001

538130 Janssen Pharmaceutica N.V.

LIVOSTIN Levocabbastine

Date extended term due to expire on 16/01/2006

548996 Merck and Co., Inc.

ZOCOR (simvastatin)

Date extended term due to expire on 19/07/2005

553845 Janssen Pharmaceutica N.V.

[Appendix 2 follows]
## APPENDIX 3

### BE

**LISTES CUMULATIVES -- CUMULATIEVE LIJSTEN**

**CERTIFICATS COMPLEMENTAIRES DE PROTECTION DES MEDICAMENTS**

**AANVUL. BESCHERMINGSCERTIFICATEN VOOR DE GENEESMIDDELEN**

### LIENE DES DEMANDES

<table>
<thead>
<tr>
<th>NÚMERO DE LA DEMANDE</th>
<th>TITULARE</th>
<th>AMP. BELGE</th>
<th>DATE DE DELIVRANCE</th>
<th>PRODUIT</th>
<th>AMP. CEE</th>
<th>DATE DE DELIVRANCE</th>
<th>PAYS</th>
<th>BREVET DE PUBLICATION</th>
<th>TITRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001/001</td>
<td>BEECH &amp; CO. INC.</td>
<td>BE</td>
<td>EU/1/99/111/001</td>
<td>EPAVIKANZ</td>
<td>/</td>
<td>/</td>
<td></td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>2002/002</td>
<td>PRE-JAY HOLDINGS LTD; WOCO INVESTMENTS LTD</td>
<td>BE</td>
<td>EU/1/02/002</td>
<td>ESTRADIOLUN / DYDROGESTERONUM</td>
<td>/</td>
<td>/</td>
<td></td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>2003/003</td>
<td>BESCHRIUS A.G.</td>
<td>BE</td>
<td>EU/1/03/003</td>
<td>1250 15 114 F12</td>
<td>/</td>
<td>/</td>
<td></td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>2004/004</td>
<td>BEECHAM GROUP P.L.C.</td>
<td>BE</td>
<td>EU/1/04/004</td>
<td>ANHYDROXYCHYLAMYLAM (degré de substitution = 0,58-0,45 ; poids moléculaire moyen = 150.000)</td>
<td>/</td>
<td>/</td>
<td></td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>2005/005</td>
<td>BEECHAM GROUP P.L.C.</td>
<td>BE</td>
<td>EU/1/05/005</td>
<td>HIBRIDILITAZONE.</td>
<td>/</td>
<td>/</td>
<td></td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>NUMERO DE LA DEMANDE</td>
<td>2801C/008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TITULAIRE</td>
<td>TSUNARA SANGYO KAIsha LTD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANN DELGE</td>
<td>28/01/2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUMERO DE DELIVRANCE</td>
<td>92209/8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRODUIT</td>
<td>FOSTHITAZATE.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANN CEE</td>
<td>28/02/1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUMERO DE DELIVRANCE</td>
<td>0522</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAYS</td>
<td>ROYADNE-UNI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BREVET DE PACE</td>
<td>EUROPEEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TITRE</td>
<td>COMPOSÉ ORGANOPHOSPHORE, PROCEDE POUR LE PREPARE ET COMPOSITION INSECTICIDE, MITICIDE OU NEMATOCIDE LE CONTENANT.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Liste des livraisons

<table>
<thead>
<tr>
<th>N° Certificat</th>
<th>Titulaire</th>
<th>Date de la livraison</th>
<th>Pays</th>
<th>Produit</th>
</tr>
</thead>
<tbody>
<tr>
<td>029 0909</td>
<td>Genetics Institute Inc.</td>
<td>02/02/01</td>
<td>BE</td>
<td></td>
</tr>
<tr>
<td>029 0900</td>
<td>Pharmacia &amp; Upjohn A.B.</td>
<td>06/09/00</td>
<td>BE</td>
<td></td>
</tr>
<tr>
<td>029 0777</td>
<td>Pharmacia &amp; Upjohn S.P.A.</td>
<td>12/07/00</td>
<td>IT</td>
<td></td>
</tr>
<tr>
<td>029 0892</td>
<td>A. Z. Nobel N.V.</td>
<td>06/09/02</td>
<td>BE</td>
<td></td>
</tr>
</tbody>
</table>

## Dates de péremption

<table>
<thead>
<tr>
<th>N° Certificat</th>
<th>Titulaire</th>
<th>Date de péremption</th>
<th>Pays</th>
</tr>
</thead>
<tbody>
<tr>
<td>029 0909</td>
<td>Genetics Institute Inc.</td>
<td>02/02/01</td>
<td>BE</td>
</tr>
<tr>
<td>029 0900</td>
<td>Pharmacia &amp; Upjohn A.B.</td>
<td>06/09/00</td>
<td>BE</td>
</tr>
<tr>
<td>029 0777</td>
<td>Pharmacia &amp; Upjohn S.P.A.</td>
<td>12/07/00</td>
<td>IT</td>
</tr>
<tr>
<td>029 0892</td>
<td>A. Z. Nobel N.V.</td>
<td>06/09/02</td>
<td>BE</td>
</tr>
</tbody>
</table>
### Liste des deliveries

<table>
<thead>
<tr>
<th>Numéro du certificat</th>
<th>2091/698</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titulaire</td>
<td>Ichikawa Sangyo Kaisha LTD</td>
</tr>
<tr>
<td>Adresse</td>
<td>3-25, Edobori, 1-chome, Kishi-ku, OSAKA 550-0002</td>
</tr>
<tr>
<td>Numéro delivrance</td>
<td>9299/B</td>
</tr>
<tr>
<td>Produit</td>
<td>POSTHIAZATE.</td>
</tr>
<tr>
<td>Date de delivrance</td>
<td>2000/2000</td>
</tr>
</tbody>
</table>

**Liste des deliveries**

2001

<table>
<thead>
<tr>
<th>Numéro</th>
<th>0522</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date de delivrance</td>
<td>2001/0522</td>
</tr>
<tr>
<td>Pays</td>
<td>RUSSIE</td>
</tr>
</tbody>
</table>

**Brevet de paie**

**Titre**

Propriété organophosphorée, procédé pour le préparer et composition insecticide, miticide ou nematicide le centnaire.

**Date de paiement**

<table>
<thead>
<tr>
<th>Date</th>
<th>07/11/2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dû</td>
<td>1826 30000</td>
</tr>
</tbody>
</table>

[Appendix 4 follows]
### SCHWEIZERISCHE EIDGENOSSENSCHAFT - CONFÉDÉRATION SUISSE - CONFEDERAZIONE SVIZZERA

#### BESCHEINIGUNG

Ober die Erteilung eines ergänzenden Schutzzertifikates für einen Wirkstoff oder eine Wirkstoffzusammensetzung mit der Nr.

<table>
<thead>
<tr>
<th>Inhaber/in</th>
<th>Pharmacie Spa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titulaire</td>
<td>Via Robert Koch 1.2 Milano (IT)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bezeichnung des Erzeugnisses</th>
<th>Désignation du produit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titolare</td>
<td>Idarubicin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Datum und Nr. der Zulassung</th>
<th>Date et no. de l'autorisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.03.1992; IKS-Nr. 50 838</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nr. des Grundpatentes</th>
<th>No. du brevet de base</th>
</tr>
</thead>
<tbody>
<tr>
<td>622 529</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Beginn der Laufzeit</th>
<th>Début de la protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.06.1996</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ablaufdatum</th>
<th>Date de l’échéance</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.06.2001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Die Eintragung des ergänzenden Schutzzertifikates erfolgt ohne Gewährleistung des Staates.</th>
<th>Le certificat complémentaire de protection est enregistré sans garantie de l’Etat</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.04.1996</td>
<td></td>
</tr>
</tbody>
</table>

### CERTIFICAT

de la délivrance d’un certificat complémentaire de protection pour un principe actif ou une composition de principes actifs no

<table>
<thead>
<tr>
<th>Inhaber/in</th>
<th>Pharmacie Spa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titulaire</td>
<td>Via Robert Koch 1.2 Milano (IT)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bezeichnung des Erzeugnisses</th>
<th>Désignation du produit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titolare</td>
<td>Idarubicin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Datum und Nr. der Zulassung</th>
<th>Date et no. de l’autorisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.03.1992; IKS-Nr. 50 838</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nr. des Grundpatentes</th>
<th>No. du brevet de base</th>
</tr>
</thead>
<tbody>
<tr>
<td>622 529</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Beginn der Laufzeit</th>
<th>Début de la protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.06.1996</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ablaufdatum</th>
<th>Date de l’échéance</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.06.2001</td>
<td></td>
</tr>
</tbody>
</table>

### CERTIFICATO

del rilascio di un certificato protettivo complementare per un principio attivo o composizione di principi attivi no.

<table>
<thead>
<tr>
<th>Inhaber/in</th>
<th>Pharmacie Spa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titolare</td>
<td>Via Robert Koch 1.2 Milano (IT)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bezeichnung des Erzeugnisses</th>
<th>Désignation du produit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titolare</td>
<td>Idarubicin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Datum und Nr. der Zulassung</th>
<th>Data e no. dell’autorizzazione</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.03.1992; IKS-Nr. 50 838</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nr. del brevetto di base</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>622 529</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Beginn della protezione</th>
<th>Inizio della protezione</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.06.1996</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data della scadenza</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15.06.2001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Die Eintragung del certificato protettivo complementare è registrato senza garanzia dello Stato.</th>
</tr>
</thead>
<tbody>
<tr>
<td>30.04.1996</td>
</tr>
</tbody>
</table>

Eldgenössisches Institut für Geistiges Eigentum
Institut Fédéral de la Propriété Intellectuelle
Istituto Federale della Proprietà Intellettuale

716 DFI 9601

Date: January 2002
### 10.11. FG3X

<table>
<thead>
<tr>
<th>CH PMMB1/FBDM/FBDM  #</th>
<th>30.4.56</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.11. FG3X</strong></td>
<td></td>
</tr>
<tr>
<td>Erteilte Zertifikate</td>
<td></td>
</tr>
<tr>
<td>Certificats délivrés</td>
<td></td>
</tr>
<tr>
<td>Certificati rilasciati</td>
<td></td>
</tr>
<tr>
<td>10.11.1. Zu nationalen Patenten</td>
<td></td>
</tr>
<tr>
<td>Se referent a des brevets nationaux</td>
<td></td>
</tr>
<tr>
<td>Referendosi a brevetti nazionali</td>
<td></td>
</tr>
<tr>
<td>19.10.1995</td>
<td></td>
</tr>
<tr>
<td>Roche AG, Basel</td>
<td></td>
</tr>
<tr>
<td>4002 Basel</td>
<td></td>
</tr>
<tr>
<td>19.03.1990</td>
<td></td>
</tr>
<tr>
<td>Actinomys</td>
<td></td>
</tr>
<tr>
<td>09.03.2000</td>
<td></td>
</tr>
<tr>
<td>Roche AG, Basel</td>
<td></td>
</tr>
<tr>
<td>4002 Basel</td>
<td></td>
</tr>
<tr>
<td>10.08.1992</td>
<td></td>
</tr>
<tr>
<td>Levamisole</td>
<td></td>
</tr>
<tr>
<td>17.10.1995</td>
<td></td>
</tr>
<tr>
<td>Sanofi</td>
<td>32-34, rue Marbeuf, Paris (FR)</td>
</tr>
<tr>
<td>Gasdarpo</td>
<td>22, Avenue Galilée, Le Plessis-Robinson (FR)</td>
</tr>
<tr>
<td>Blood AG</td>
<td>3000 Bern 25</td>
</tr>
<tr>
<td>601 290</td>
<td></td>
</tr>
<tr>
<td>Precede de preparation de derives de pyrimidine.</td>
<td></td>
</tr>
<tr>
<td>DBCM-no 49068 / 24.11.1992</td>
<td></td>
</tr>
<tr>
<td>Triozoline</td>
<td>14.01.1999</td>
</tr>
<tr>
<td>10.03.1995</td>
<td></td>
</tr>
<tr>
<td>Roche AG, Basel</td>
<td></td>
</tr>
<tr>
<td>4002 Basel</td>
<td></td>
</tr>
<tr>
<td>10.08.1992</td>
<td></td>
</tr>
<tr>
<td>Kortone</td>
<td></td>
</tr>
<tr>
<td>10.10.1995</td>
<td></td>
</tr>
<tr>
<td>Sanofi</td>
<td>32-34, rue Marbeuf, Paris (FR)</td>
</tr>
<tr>
<td>Gasdarpo</td>
<td>22, Avenue Galilée, Le Plessis-Robinson (FR)</td>
</tr>
<tr>
<td>Blood AG</td>
<td>3000 Bern 25</td>
</tr>
<tr>
<td>601 290</td>
<td></td>
</tr>
<tr>
<td>Precede de preparation de derives de pyrimidine.</td>
<td></td>
</tr>
<tr>
<td>DBCM-no 49068 / 24.11.1992</td>
<td></td>
</tr>
<tr>
<td>Triozoline</td>
<td>14.01.1999</td>
</tr>
<tr>
<td>10.03.1995</td>
<td></td>
</tr>
<tr>
<td>Roche AG, Basel</td>
<td></td>
</tr>
<tr>
<td>4002 Basel</td>
<td></td>
</tr>
<tr>
<td>10.08.1992</td>
<td></td>
</tr>
</tbody>
</table>

[Appendix 5 follows]
Appendix 5

ČESKÁ REPUBLIKA
ÚŘAD PRŮmysLOVÉHO VLASTNICTVÍ

DODATKOVÉ OCHRANNÉ OSVĚDČENÍ
K PATENTU Č.

Číslo osvědčení:
Majitel osvědčení:
Název přípravku:
Číslo první registrace:
Datum první registrace:
Rozhodnutí o registraci vydal:
Platnost osvědčení do:

V Praze dne...

Za předsedou:

[Appendix 6 follows]

Sie enthält folgende Angaben:

Bezeichnung der Erfindung

Name und Anschrift des Anmelders

Nummer(n) und Zeitpunkt der Genehmigung des Bundesgesundheitsamts (BGA) bzw. des Instituts für Arzneimittelwesen der ehemaligen DDR (IfA)

Bezeichnung des Erzeugnisses

Gegebenenfalls Land, Nummer und Zeitpunkt der ersten Genehmigung für das Inverkehrbringen in der Gemeinschaft (EG).

Zertifikatsanmeldungen:

DE

CPTC 22539


CPTD 209983

Derivate der 3-(endo-2-Azahexylcyclo-3,3,3-tri-1-carbonmethylen, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. Hoecht AG. BGA: 9011 02 02 vom 26.06.90

Rampaur E.G. Frankreich. NL 1554 vom 10.01.90

CPTD 211358

Verfahren zur Herstellung von Allylamin. Janssen Pharmaceutica N.V. Cornishuevanen 30, B 2340 Breese, BE BGA: 1332 00 01, 1332 01 01 vom 18.06.90

Chem-A. Blomstoffen. EG. Frankreich. NL 15156 vom 20.06.90

CPTC 22539


CPTD 209983

Derivate der 3-(endo-2-Azahexylcyclo-3,3,3-tri-1-carbonmethylen, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. Hoecht AG. BGA: 9011 02 02 vom 26.06.90

Rampaur E.G. Frankreich. NL 1554 vom 10.01.90

CPTD 211358

Verfahren zur Herstellung von Allylamin. Janssen Pharmaceutica N.V. Cornishuevanen 30, B 2340 Breese, BE BGA: 1332 00 01, 1332 01 01 vom 18.06.90

Chem-A. Blomstoffen. EG. Frankreich. NL 15156 vom 20.06.90

Hoecht AG

Fonfach GRM 30, 6230 Frankfurt B. DE

BGA: 9014 00 00, 9014 01 01 vom 01.01.93

Trendelburger E.G. Frankreich. NL 1554 vom 10.01.90

CPTD 209983

Derivate der 3-(endo-2-Azahexylcyclo-3,3,3-tri-1-carbonmethylen, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. Hoecht AG. BGA: 9011 02 02 vom 26.06.90

Rampaur E.G. Frankreich. NL 1554 vom 10.01.90

CPTD 211358

Verfahren zur Herstellung von Allylamin. Janssen Pharmaceutica N.V. Cornishuevanen 30, B 2340 Breese, BE BGA: 1332 00 01, 1332 01 01 vom 18.06.90

Chem-A. Blomstoffen. EG. Frankreich. NL 15156 vom 20.06.90

CPTD 209983

Derivate der 3-(endo-2-Azahexylcyclo-3,3,3-tri-1-carbonmethylen, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. Hoecht AG. BGA: 9011 02 02 vom 26.06.90

Rampaur E.G. Frankreich. NL 1554 vom 10.01.90

CPTD 211358

Verfahren zur Herstellung von Allylamin. Janssen Pharmaceutica N.V. Cornishuevanen 30, B 2340 Breese, BE BGA: 1332 00 01, 1332 01 01 vom 18.06.90

Chem-A. Blomstoffen. EG. Frankreich. NL 15156 vom 20.06.90

Appendix 7 follows
Ansøgninger om supplerende beskyttelsescertifikat

(21) Ans. nr: CA 1999 00033
(22) Indlag: 1999-12-21
(66) Grundpatent nr: PR 166880
(71) Ansøger: Exalgy, 6, rue Christophe Colomb, F-75008
Paris, Frankrig
(74) Fuldmægtig: Patentbureauet, Magnus Jønssens Eft., Frederiksbergvej 15, 3520 Farum, Danmark
(92) DK markedsførelsestilladelse nr: 30741
(92) Dato for samme: 1999-08-27
(95) Produkt: Milfeprilat
(93) Farvare markedsføringstilladelse
   I EU: 558473.0 (FR)
(93) Dato for samme: 1995-08-27
(54) Benævnelse: Milfeprilat

(21) Ans. nr: CA 1999 00034
(22) Indlag: 1999-12-22
(66) Grundpatent nr: 0479363
(71) Ansøger: MERCK & CO. INC., 126, East Lincoln Avenue, P.O. Box 2000, Rahway, New Jersey 07065-0990, USA
(74) Fuldmægtig: Hoffmann-La Roche, Lehmann & Rea A/S, Hans Bekkervolds Allé 7, 2900 Hellerup, Danmark
(92) DK markedsførelsestilladelse nr: 30290, 30291
(92) Dato for samme: 1999-07-12
(95) Produkt: Ticlofilinhydrochlorid monohydrat
(93) Farvare markedsføringstilladelse
   I EU: 54761 (CH)
(93) Dato for samme: 1999-09-25
(54) Benævnelse: Ticlofilinhydrochlorid monohydrat

(21) Ans. nr: CA 1999 00035
(22) Indlag: 1999-12-23
(66) Grundpatent nr: 0477205
(74) Fuldmægtig: Budde, Schou & Ostenfeld A/S, Vejle Sagade, 10, 1801 København V, Danmark
(92) DK markedsførelsestilladelse nr: K(1999) 1901
(92) Dato for samme: 1999-07-01
(95) Produkt: Epilfibrild
(93) Farvare markedsføringstilladelse
   I EU: K(1999) 1901
(93) Dato for samme: 1999-07-01
(54) Benævnelse: Epilfibrild

[Appendix 8 follows]
APPENDIX 8

TÄIENDAVA KAITSE TUNNISTUS

TUNNISTUS ON VALJA ANTUD ENNI RASJU SACUSE ÜLE 97. JÄRGI.

TUNNISTUST TŠENIISI LEITISET REGISTRERINGUST TULENENUTA ÖIGUSTE KEHTIVUSE PIKENDAMIST TUNNISTUSTES MÄRGITUD PÄTNI KEHTIVUSAJALÖPPMISEL TUNNISTUSTES NIMETATUD TOOTES KAITSE TUNNISTUSTES MÄRGITUD AJAL.

TÄIENDAVA KAITSE KAITSE TUNNISTUSTES MÄRGITUD AJAL KUI ISA KEHTIVUSAJASTA EEST ON TASUTUD RIIGIÖÖ.
APPENDIX 9

13. CERTIFICADOS COMPLEMENTARIOS DE PROTECCION (REGLAMENTO CEE 1768/92 Y CE 1610/96)

SOLICITUDES

<table>
<thead>
<tr>
<th>N.°</th>
<th>Certificado</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>C9900013</td>
</tr>
<tr>
<td>22</td>
<td>26-03-1999</td>
</tr>
<tr>
<td>26</td>
<td>Adir, S.A.R.L., 1, Rue Carle Hébert, 92415 Courbevoie Cedex, Francia.</td>
</tr>
<tr>
<td>36</td>
<td>8305723</td>
</tr>
<tr>
<td>29</td>
<td>Procedimiento de preparación de nuevos diácidos sustituidos y sus sales.</td>
</tr>
<tr>
<td>33</td>
<td>Perindopril (Bi Preterax).</td>
</tr>
<tr>
<td>45</td>
<td>62407 de 09-12-1998</td>
</tr>
<tr>
<td>54</td>
<td>NL 21997 de 05-10-1998</td>
</tr>
</tbody>
</table>

RESOLUCIONES

Las resoluciones que se insertan en este capítulo no son definitivas en la vía administrativa, pudiendo interponease contra las mismas recurso de alzada en el plazo de 1 mes ante el Ilmo. Sr. Dtor. de la Oficina Española de Patentes y Marcas.

DENEGACIONES

<table>
<thead>
<tr>
<th>N.°</th>
<th>Certificado</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>C9900016</td>
</tr>
<tr>
<td>22</td>
<td>09-04-1999</td>
</tr>
<tr>
<td>26</td>
<td>Laboratorios Farmacéuticos Ravi, S.A.</td>
</tr>
<tr>
<td>36</td>
<td>2003197</td>
</tr>
<tr>
<td>29</td>
<td>Procedimiento para la despolimeración de la heparina para la obtención de una heparina de bajo peso molecular dotada de actividad antitrombótica.</td>
</tr>
<tr>
<td>33</td>
<td>Hibor.</td>
</tr>
<tr>
<td>33</td>
<td>61907/61908 16-04-1998</td>
</tr>
</tbody>
</table>

Fecha denegación: 27-10-2000

Motivos: Subsisten defectos que no han sido debidamente subsanados en el plazo previsto al efecto según lo establecido en el artículo 10.4 del Reglamento (CEE) N° 178892.
SOLICITUDES

<table>
<thead>
<tr>
<th>Núm.</th>
<th>Ref.</th>
<th>Fecha</th>
<th>Empresa y Dirección</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>C9800032</td>
<td>27.10.1998</td>
<td>Glaxo Group Limited, Berkeley Avenue, Greenford, Middlesex UB6 0NN, Gran Bretaña.</td>
</tr>
</tbody>
</table>

RESOLUCIONES

Las resoluciones que se insertan en este capítulo no son definitivas en la vía administrativa, pudiendo interponerse contra las mismas recurso de alzada en el plazo de 1 mes ante el Ilmo. Sr. Dtor. de la Oficina Española de Patentes y Marcas.

CONCESIONES

<table>
<thead>
<tr>
<th>Núm.</th>
<th>Ref.</th>
<th>Fecha</th>
<th>Empresa y Dirección</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>C9800011</td>
<td>26.03.1998</td>
<td>Zeneca Ltd., 15 Stanhope Gate, London W1Y 6LN, GB</td>
</tr>
<tr>
<td>23</td>
<td>C9800027</td>
<td>29-09-1998</td>
<td>Otsuka Ph., 9 Kandatsukasa-cho, 2-chome, Chiyoda-ku, 101 Tokyo, JP</td>
</tr>
</tbody>
</table>

[Appendix 10 follows]
APPENDIX 10

FR

BOPI 93/30

195

QUATRIÈME PARTIE

PUBLICATION DES CERTIFICATS COMPLEMENTAIRES DE PROTECTION

SOMMAIRE


1. Liste des demandes de certificats complémentaires de protection rendues publiques ................................................................. 197
2. Liste des certificats complémentaires de protection délivrés .............. 199


1. Liste des demandes de certificats complémentaires de protection rendues publiques ................................................................. 201
2. Liste des demandes de certificats complémentaires de protection rejetées  Néant
3. Liste des certificats complémentaires de protection délivrés .............. Néant

Date: January 2002
BOPI 93/30

DEMANDES DE CERTIFICATS COMPLÉMENTAIRES DE PROTECTION RENDUES PUBLIQUES

Règlement ( CEE ) N° 1768/92 du conseil du 18 juin 1992

Numero national : 93CD0004 déposé le 11-02-93
Demandeur : TAKEDA CHEMICAL INDUSTRIES, LTD, 1-1, Osaka-machi 4-chome, Chuo-ku OSAKA 541 (JP)
Référence du brevet de base :
N° d'enregistrement national : FR 74 32580 déposé le 27-09-74
N° de publication : 2245375 délivré le 10-07-78
Titre de l'invention : Nouveaux Amidés Nonapeptides

Numéro de la 1ère A.M.M. en France : NL 15229
Date de la 1ère A.M.M. en France : 16-08-88
Produit identifié par l'A.M.M. en France : LEUPRORELIN

Numero national : 93CD0010 déposé le 01-04-93
Demandeur : CETUS ONCOLOGY CORPORATION, 1400 Fifty-third Street, EMERYVILLE CALIFORNIA 94608 (US)
Référence du brevet de base :
N° de dépôt européen : EP 83 306221 déposé le 13-10-83
N° de publication : 0109748 délivré le 13-04-88
Titre de l'invention : Préparations pharmaceutiques et vétérinaires d'interleukine-2 mutée au niveau de la cystéine-125 (mutée), et leur production

Numéro de la 1ère A.M.M. en France : NL 15585
Date de la 1ère A.M.M. en France : 15-09-89

Numéro de la 1ère autorisation dans la C.E.E. : 13282
Date de la 1ère autorisation dans la C.E.E. : 03-07-89

en / 07-07-01

Date: January 2002
DEMANDES DE CERTIFICATS COMPLÉMENTAIRES DE PROTECTION REJETÉES

Reçu en CE N° 1768/92 du Conseil du 18 juin 1992

- Numéro national: 90C0008
- Demandeur: ALCATEL TRANSMISSION FAISCEAUX H
  84 RUE DE LA LIBERTE, 38300 BOURGOIN JALLIEU
  (FR)
- Numéro du brevet de base: EP 81 102 132
- Titre de l'invention: Formulation ophtalmique stabilisée
- Numéro de la 1ère A.M.M. en France: NL 13433
- Date de la 1ère A.M.M. en France: 12/05/90
- Produit identifié par l'A.M.M. en France: Trimepsprim
  Polymyxin B SULFATE
- Numéro de la 1ère autorisation dans le C.E.E.: 
- Date de la 1ère autorisation dans le C.E.E.: 

FR

en / 07-07-01

Date: January 2002
FR

CERTIFICATS COMPLÉMENTAIRES DE PROTECTION DÉLIVRÉS
Règlement (CEE) N° 1768/92 du conseil du 18 juin 1992

- numéro national : 93C008
- Date limite de validité : 15/10/98
- Titulaire: ALCATEL TRANSMISSION FAISCEAUX H
  84 RUE DE LA LIBERTE, 38300 BOURGOIN JALLIEU
  (FR)
- Numéro du brevet de base : EP 81 102 132
- Titre de l'invention : Formulation ophthalmique stabilisée
- Numéro de la 1ère A.M.M. en France : NL 13433
- Date de la 1ère A.M.M. en France : 12/05/90
- Produit identifié par l'A.M.M. en France : Trimethoprim -
  Polymétylin SULFATE
- Numéro de la 1ère autorisation dans le C.E.E. :
- Date de la 1ère autorisation dans le C.E.E. :

[Appendix 11 follows]
APPENDIX 11

GB

10 May 2000 No. 5791

THE PATENTS AND DESIGNS JOURNAL

Application Numbers: GB 0006435.2 - GB 0007067.2
Publication Numbers: GB 2343353 - GB 2343605

Price £12.25

Contents

i General Information

ii OFFICIAL NOTICES

PROCEDINGS UNDER THE PATENTS ACT 1977

1999 Applications for Patents filed

2015 Applications terminated

Applications published:

2017 Subject-Matter Index

2033 Number Index

2035 Name Index

Patents granted:

2045 Number Index

2058 Subject-Matter Index

2060 Name Index

2069 European Patents granted

2094 Translations filed

2101 European Patents void

2101 European Patents revoked

2102 European Patents ceased

2104 European Patents expired

2105 UK Patents ceased

2106 UK Patents expired

2107 Other Proceedings under the Patents Act 1977

(Sections 27, 28, 30, 32, 46, 73, 75, 89A(6))

PROCEDINGS UNDER EC REGULATIONS 1768/92 and 1610/96

2113 (Supplementary Protection Certificates for Medicinal Products and Plant Protection Products, respectively)

PROCEDINGS UNDER THE REGISTERED DESIGNS ACT 1949

2114 Certificates of Registration issued

2117 Designs extended

THE BRITISH LIBRARY
Proceedings under EC Regulations 1768/92 and 1610/96
(Supplementary Protection Certificates for Medicinal Products and Plant Protection Products, respectively)

These entries include details of all proceedings relating to Supplementary Protection Certificates. Applications for Supplementary Protection Certificates are numbered in a single yearly sequence commencing SP/GB93/001 covering both medicinal and plant protection products and the same number is retained for the granted certificate. Proceedings are open to public inspection but the granted certificate is not separately published.

The entries are grouped in categories according to the type of proceedings. Within each category the entries are arranged in alphabetical order according to the name of the applicant for, or holder of, the certificate and provide the following information: the name and address of the applicant or holder; the product in respect of which the certificate has been applied for or granted; the product type; i.e., "Medicinal" or "Plant Protection"; the number and date of the first authorisation under Directive 65/65/EEC or Directive 81/851/EEC to place the product on the market as a medicinal product in the United Kingdom or the number and date of the first authorisation under Article 4 of Directive 91/414/EEC or an equivalent provision of national law to place the product on the market as a plant protection product in the United Kingdom; where relevant, the country; number and date of the first authorisation to place the product on the market in the European Community; the number and title of the basic UK patent or European patent (UK) which protects the product; and the number of the application or certificate.

The entries will also state as appropriate: the filing date of the application; the date of grant or rejection of the application; the maximum period of the granted certificate; the effective period of the certificate on entry into force; and the date of lapse or invalidity of the certificate.

There follows three examples of entries under these proceedings. The first relates to a new application for a certificate based on an European patent designating the United Kingdom and having first authorisation of the product in the United Kingdom. The second example relates to a certificate granted based, once again, on a European patent designating the United Kingdom but with the first product authorisation in the EEC in Denmark. The third refers to a certificate entering into force based on a United Kingdom patent with first product authorisation in the EEC in Belgium.

**Example 1: Applications for Certificates Filed**

(71) Omneda Pharmaceutical Products Division Inc.
110 Allen Road, Liberty Corner, NJ 07938 USA

(95) Product: 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane ("Desflurane")

(92) Authorised: UK 00282012U 19 July 1993

(68) Patent No: EP(UK) 0283237 (54) 2- (Difluoromethoxy)-1,1,2-tetrafluoroethane as an anesthetic

(21) SP/CGB93/175

(22) Lodged: 24 December 1993

**Example 2: Certificates Granted**

(73) Aktiebolaget Hassle
Karolinska 5,5-431 83 Mohdala, Sweden

(95) Product: Felodipine

(92) Authorised: UK 00170235-0236 15 November 1993

(68) Patent No: EP(UK) 0007293 (54) 2,5,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ether-5-ethyl ester having hypnotic properties, process for its preparation and pharmaceutical preparations containing it.

(21) SP/CGB93/134

(94) Maximum period expires: 20 January 2003

**Example 3: Certificates entered into force**

(73) American Cyanamid Company
Burden Avenue, Towsphip of Wayne, State of New Jersey 06904, United States of America

(95) Product: Felpinac (4-biphenyl acetic acid)

(92) Authorised: BE 536 15 91 F 7 28 October 1988

(68) Patent No: GB 1402691 (54) Compositions of 4-Biphenyl Acetic Acid

(11) SP/CGB93/151

(24) Data entered into force: 7 September 1993

(94) Effective period expires 6 September 1998
Appendix 11, page 3

COPY OF CERTIFICATE GRANTED
ON SPC/GB 93/039

EEC Regulation No. 1768/92

Supplementary Protection Certificate

In accordance with Article 10(1) of the above Regulation, Supplementary Protection Certificate No SPC/GB93/039 is hereby granted to Ciba-Geigy AG, in respect of the product

Cyromazine

protected by basic patent No GB 1587573 entitled "2-Cyclopropylamino-4,6-diamino-s-triazine derivatives and their use as insecticides".

This certificate will take effect (subject to the payment of the prescribed fees) at the end of the lawful term of the basic patent and its maximum period of duration in accordance with Article 13 will expire on 17 August 2002, subject to the provisions of Articles 14 and 15.

Dated this 1st day of July 1993

P.R.S. HARTNACK
Comptroller-General of Patents,
Designs and Trade Marks.

THE PATENT OFFICE
Newport, Gwent
APPENDIX 12

Gazette announcements showing (1) receipt of application for an SPC and (2) grant of SPC

(1) Request for Grant of Supplementary Protection Certificate
The name and address of the requester follow the number allocated to the request. The date in brackets following the name and address is the date of receipt of the request. The patent number is that under which the product in respect of which a certificate is sought is, allegedly, protected. Market authorisation references in respect of the product concerned are also shown.

SPC 2000003 PHARMACIA & UPJOHN S.P.A.,
Via Robert Koch, 1.2, 20152 Milano, Italy
(22 February 2000)
Patent No: 58949; SUBSTITUTED ANDROSTA-1,4-DIENE-3,17-DIONES AND PROCESS FOR THEIR PREPARATION
Product: Exemestane
Market Authorisation: Ireland PA 16/83/1
12 November 1999
United Kingdom PL 00032/0236
16 December 1998

(2) Supplementary Protection Certificates Granted
The name and address of the grantee follow the number allocated to the application for grant of a certificate; this number applies also to the granted certificate. The date in brackets following the name and address is the date of grant of the certificate. The number of the basic patent and the title of the invention are followed by the name of the product for which the certificate is granted. Market authorisation references in respect of the product concerned are also shown, followed by the date of expiry of the certificate.

SPC 1999009 MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,
18 rue Dicks, L 1417 Luxembourg
(09 August 1999)
Patent No: 48802, Mercapto derivatives of substituted prolines
Product: Zofenopril and its salts, in particular its calcium salt
Market Authorisation: Ireland, PA865/3/1-4 and PA865/4/1-4
04 March 1999
United Kingdom, PL 16239/0002-0005
30 July 1998
Certificate expires on: 09 August 2004

[Appendix 13 follows]
APPENDIX 13

MINISTERIO DELL’INDUSTRIA
DEL COMERCIO E
DELL’ARTIGIANATO

DIREZIONE GENERALE DELLA
PRODUZIONE INDUSTRIALE

OFFICIO ITALIANO BREVETTI E MARCHI
- ROMA -

BOLLETINO UFFICIALE DEI
CERTIFICATI COMPLEMENTARI
DI PROTEZIONE PER I
MEDICINALI

FEBBRAIO
1996
BOLLETINO UFFICIALE
DEI CERTIFICATI COMPLEMENTARI DI PROTEZIONE
PER I MEDICINALI
(FEBBRAIO 1996)

INDICE

Elenco delle domande di C.C.P. ex Reg. C.E.E. n. 1768/’92
(n. UB96CCP522) .................................................................................................................... 1

Elenco dei C.C.P. concessi ex Reg. C.E.E. N. 1768/92’
(del 18/6/’92 (nn. 420 - 421 - 520 - 522) ................................................................. 2

Revoche (nn. 422 - 423) ................................................................. 4

Annotazioni (n. 380) ........................................................................................................... 5
N. UB96CCPS22: DEP. 02/02/96

DENOMINAZIONE: "RENORMAL" E "SETRILAN" (SIRAPRIL CLORIDRATO)

TITOLARE: SCHERING CORPORATION

di nazionalità: STATUNITENSE
indirizzo: 2000 GALLOPING HILL, RENILWORTH, NEW JERSEY 07033 (U.S.A.)

RAPPRESENTANTE: RICCARDI SERGIO

dello Studio: UFFICIO BREVETTI RICCARDI & CO.
indirizzo: VIA MACEDONIO NELONI, 32 20139 MILANO

BREVETTO N. 274168/E/95 DEL 15/10/81 (BREV. EUR. N. 0.050.800)

Autorizzazione all'immissione in commercio (Decreto del Ministero della Sanità)
rilasciata in data: 31/08/95 (nn. 547-546/1995)

Titolo dell'invenzione: "CARBOSSIDIFICI DIPEPTIDI, PROCEDURE PER LA LORO PRODUZIONE E COMPOSIZIONI FARMACUTICHE CHE LI CONTENGONO".

: ITALIA: LE AIC HANNO NN. 028582017 E 028583018 DEL 21/08/95.
: " IL NOME COMMERCIALE E' "RENPRESS". 
Appendix 13, page 4

IT

BUCCP 02/96
CONCESSIONI EX REGOLAMENTO C.E.E. N.1788/92 p. 2

N. C-UB993CPC420: DEP. 01/03/93 CONC. IL 21/02/1996

DEMONINAZIONE: RECUPERO EN ANTIGIENE DEL VIRE DI TERSIER E VACCINO
CONTRO L'EPATITE B.

TITOLARE: BIOCEN, INC.
di nazionalità: STATI UNITI
indirizzo: CAMBRIDGE, MASSACHUSETTS, U.S.A.
RAPPRESENTANTE: RICCARDI S.
dello studio: UFF. BREVETTI RICCARDI & CO.
indirizzo: V. M. HELLONI, 21, 20129 MILANO

BREVETTO N. 2032588 DEL 25/03/87 DEP. 21/12/79 BREV. EUR. 0.013.628
Autorizzazione all'immissione in commercio (Decreto del Ministero della Salute)
rilasciata in data: 30/06/88

Titolo dell'invenzione:
"ERRE RECIPIENTE DEPOT TRAFORATO CON ESSO E POLIPEROTIDE
PRODOTTO DELL'USO PER LA PREPARAZIONE METODO DI RILISTENZIATI INFISSERANO IL POLIPEPTIDE"
Durata del CCP: 1 ANNO, 4 MESI, 25 G.I. DAL 21/11/1999

ITALIA: L'A.I.C. RA NN. 026710018, 026710020 (20/6/1988);
GERMANY: L'A.I.C. RA NN. 50a/85, 50a/86, 50a/86 (16/3/1986);
"IL PRODOTTO E' DEPOTILATO "GEN-2-DEL VAL".

N. C-UB993CPC421: DEP. 01/03/93 CONC. IL 21/2/1996

DEMONINAZIONE: AMENI B ANTIGIENE DEL VIRE DI TERSIER E VACCINO
MONOAGGI ANTIVIRICI.

TITOLARE: BIOCEN, INC.
di nazionalità: STATI UNITI
indirizzo: CAMBRIDGE, MASSACHUSETTS, U.S.A.
RAPPRESENTANTE: RICCARDI S.
dello studio: UFF. BREVETTI RICCARDI & CO.
indirizzo: V. M. HELLONI, 21, 20129 MILANO

BREVETTO N. 2262983 DEL 11/07/90 DEP. 21.12.79 BREV. EUR. 0.182.442
Autorizzazione all'immissione in commercio (Decreto del Ministero della Salute)
rilasciata in data: 18/09/87

Titolo dell'invenzione:
"MOLECOLE DI ERA RICOSINANTE E METODO PER LA PREPARA-
ZIONE"
Durata del CCP: 1 ANNO, 10 MESI, 24 G.I. DAL 21/12/99

ITALIA: L'A.I.C. RA NN. 026653016/18/30/42 (18/9/1987);
BELGIO: L'A.I.C. RA NN. 18 5 394 F 17 (14/1/1986).

N. C-UB96CCP520: DEP. 10/01/96 CONC. IL 22/02/1996

DEMONINAZIONE: "EMEREX" E "EMEREX" METODO PER LA PREPARA-
ZIONE

TITOLARE: PFIZER INC.
di nazionalità: STATI UNITI
indirizzo: NEW YORK, U.S.A.
RAPPRESENTANTE: ING. G. MOSSANO
dello studio: MOSSANO & ASSOCIATI
indirizzo: VIA MEXAVIGLIE, 14, 20129 MILANO

BREVETTO N. 2467585 DEL 23/06/89 DEP. 15/03/85 (BREV. EUR. 0.156.603)
Autorizzazione all'immissione in commercio (Decreto del Ministero della Salute)
rilasciata in data: 11/08/95 (n. 536/1995)

Titolo dell'invenzione:
"-ODIVIOYCO-L-CARBOSSIDI CO-GIOSI AGGIUNTEGGI AN
ALGISDI ED ANTI-INFLAMMATORI"
Durata del CCP: 4 ANNO, 6 MESI, 6 G.I. DAL 15/1/2005

ITALIA: LE A.I.C. RA NN. 028229014-10-12/46, 02998016-16-10-43
DELL'11/11/89;

en / 07-07-01

Date: January 2002
- In data 16/2/1996 si è provveduto a revocare il CCP sopra indicato (su richiesta del Titolare) concesso nel mese di Dicembre 1995.
- BREVETTO N. 20325/BE/87 CONC. 25/03/87 DEP. 21/12/79 (brev. eur. n. 0.013.828)
- denominazione "ENGERIX B" (ANTIGENE DEL VIRUS DELL' EPATITE B), VACCINO MONODOSE ANTIEPATITE)
- Titolare: BIOGEN INC.

- In data 16/2/1996 si è provveduto a revocare il CCP sopra indicato (su richiesta del Titolare) concesso nel mese di Dicembre 1996.
- BREVETTO N. 22629/BE/90 CONC. 11/07/90 DEP. 21/12/79 (brev. eur. n. 0.182.422)
- denominazione "RECOMBIVAX HB (ANTIGENE DEL VIRUS DELL’ EPATITE B), VACCINO CONTRO L’ EPATITE B)
- Titolare: BIOGEN INC.
UB92CCP380

- Il Ministero della Sanità ha modificato la denominazione della specialità medicinale HYPOGON in “GLUCAGEN”;
- Il CCP sopra indicato, concesso il 5/06/1995, viene corretto con la nuova denominazione;
- BREVETTO N. 20337/BE/90 CONC. IL 13/12/89
  DEP. il 20/01/86 (brev. eur. n. 0189998)
- denominazione: “GLUCAGEN”
- Titolare: NOVO NORDISK A/S
### APPENDIX 14

<table>
<thead>
<tr>
<th>特許号</th>
<th>申請番号</th>
<th>資格を求める請願の期間</th>
<th>特許法第21条の1項の残業で定められる処分の内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 - 700001</td>
<td>1100366</td>
<td>2001年9月12日</td>
<td>(1) 特許権の存続期間の延長登録の理由となる処分</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. 流行、飲料等の製造等についての処分</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(3) 特許権の存続期間の延長登録の理由となる処分</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. 流行、飲料等の製造等についての処分</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(4) 特許権の存続期間の延長登記の理由となる処分</td>
</tr>
</tbody>
</table>

- 公開日の申請者名 |
- 住所 |
- 三共株式会社（株名取締役） |
- 住所：東京都中央区日本橋本町3丁目5番1号

### Examples and IPO practices

Details on the authorization (i.e., required for registration of SPCs) under the JP Patent Law 67 - (2)
<table>
<thead>
<tr>
<th>Patent number</th>
<th>Date of registration</th>
<th>Terms of registration</th>
<th>Publication of grant of SPC</th>
<th>Name of the SPC</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>051904</td>
<td>3.2.22</td>
<td>5年</td>
<td>特許権の有効期間の延長登録の理由となる</td>
<td>アポロット・ラピッド</td>
<td>アポロット株式会社</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>根本法第14条第1項に規定する根拠に基づく理由を指定し、法律に基づく登録の承認</td>
<td>サガワラ・フォーグリュー</td>
<td>スタート・メディア</td>
</tr>
</tbody>
</table>
MINISTERE DE L'ECONOMIE
SERVICE DE LA PROPRIETE INTELLECTUELLE

CERTIFICAT COMPLEMENTAIRE DE PROTECTION POUR MEDICAMENT

Règlement CEE No 1768/92 du Conseil du 18.06.1992
concernant la création d’un certificat complémentaire de protection pour les médicaments

Date de délivrance du certificat complémentaire:  X
Numéro du certificat complémentaire:  X
Titre du certificat complémentaire:
Titulaire:  X
  X
  X

Date de dépôt et Numéro du brevet de base:  X
Titre du brevet de base:
Date de la première autorisation de mise sur le marché dans la CEE  X

Ce certificat prendra effet à l’expiration du brevet de base.

Vu l’article 13 du règlement CEE No 1768/92 le certificat complémentaire de protection viendra à terme le 00.00.0000

Mandataire:

Luxembourg, le
Pour le Ministre de l’Economie
Serge Allegrezza
Attaché de Gouvernement

[Appendix 16 follows]
LV

Patenta spēkā esamības termiņu pārārīnāšana

Pieteikumi patenta spēkā esamības termiņu pārārīnāšanai
(L.R. Patente likuma 7(9), 31(5) pārsk.)

(92) Jārunočas: lietderīgas registrēšanas apliecības numurs
un iesniegšanas datums.
(94) Datums, līdz kuram patente darbības
termiņš.
(95) Produktas nosaukums patente.
(96) Patentspēkā esamības termiņš.
(97) Patentna numurs, patente pārārīnāšanas datums.

(21) C-99-02 (22) 13.09.1999
(54) jauni sulfonamidu fibrinolīna receptora antagonisti
(73) MERCO & CO., 126, East Lincoln Avenue, P.O.Box
2000, Rathway
(74) Abrahams FOEELS, Patentu birojs "ALFA-PATENTS",
Višņes iela 2, Rīga LV-1073, LV
(92) 99-0206, 17.03.1999;
(95) C-99-0206, 17.03.1999;
(96) 89-287, 27.09.1990
(97) 5746, 23.08.1997;

Pagarinātie patentu spēkā esamības termiņi

(21) C-99-01 (22) 02.06.1999
(54) Benzimidazola atvasinājumi; to iegūšana un
izmantotā ārstētavos un farmaceitiskā kompozīcijas
(73) Takeda Chemical Industries Ltd., 1-1,
Doshomachi 4-chome, Chuo-ku, Osaka 541-0045
Japan;
(74) Vladimir ANOHNIS, Agentūra "TRIA ROBIT,
Alizkraukles iela 23, Rīga LV-1006, LV
(92) 99-0117, 17.02.1999;
(94) 17.02.2014
(95) 1-[Cikloheksiloksiokarboniloksi]-eth-2-etoaksi-1-[[H-
heptazol-5-ilojienil-4-ilojienilbenzimidazol-7-karbonilī]
stabilis kristāls (ATACANO);
(96) P-92-567, 30.12.1992
(97) 10258, 20.04.1995;

This is an announcement concerning application
for SPC.

This is an announcement concerning extended
patent term.

The difference is in a date
marked by (94).

[Appendix 17 follows]
APPENDIX 17

3 juli 2000, nr. 7
De Industriële Eigendom

Rubriek AC. Aanvragen voor een aanvullend beschermingscertificaat voor geneesmiddelen.

(Rubriek AC) Onderdeel 1. Opsomming in nummervolgorde.

- 300036
- 16.05.2000
- EP 0403159
- Imidazolylelinezuurderivaten.
- Mr. W.A. Prins c.q. te 2588 DH Den Haag.
- RVG 22269 06.01.1998
- RVG 22269 06.01.1998
- RVG 22269 06.01.1998
- Frosertan.
- 39573.06.00 27.06.1997
- 39573.01.00 27.06.1997
- 39573.02.00 27.06.1997

(Rubriek AC) Onderdeel 2. Opsomming van de in onderdeel 1 genoemde aanvragen voor een beschermingscertificaat in alfabetische volgorde van de namen van de aanvragers.

- 300036
- 16.05.2000
Rubriek KC. Verlening van aanvullende beschermingscertificaten voor geneesmiddelen.

(Rubriek KC) Onderdeel 1. Opsomming in nummervolgorde.

1000 De industriële Eigendom 3 juli 2000, nr. 7

990017
Pharmacia & Upjohn Aktiebolag te Stockholm, Zweden (SE).
Dr. R. Jorritsma c.q. te 2517 KZ Den Haag.
EP 0121038
Produkt voor geregelde triglyceride-
voeding van hyperlipideemie

25535 06.02.1999
Triglyceride Structurae Purificatae.
13302 11.10.1996
Zie volgende kolom

25535 06.02.1999
Triglyceride Structurae Purificatae.
13302 11.10.1996
Zie volgende kolom

990038
THE UNITED STATES OF AMERICA as
represented by the Secretary United
States Department of Commerce te
Springfield, Virginia 22161, Verenigde
Staten van Amerika (US).
Mr. G.L. Kooy c.q. te 2514 BD Den
Haag.
20.06.2004 25.06.2009
EP 0130905
Genetische herangezichting van
rotavirusen voor de productie van
evacins en vaccinvoorlopers.
EU/150/105/061 07.06.1999
Combinatie van rhese rotavirus
erotype 3, reassortant rhese/humaan
rotavirus serotype 1, reassortant
rhese/humaan rotavirus serotype 2
en reassortant rhese/humaan
rotavirus serotype 4.
EU/150/105/061 07.06.1999
03.01.2006/01

(Rubriek KC) Onderdeel 2. Opsomming van de in onderdeel 1 genoemde verleende
beschermingscertificaten in alfabetische volgorde van de namen van de certificatohouders.

Pharmacia & Upjohn Aktiebolag te
Stockholm, Zweden (SE).
990017
THE UNITED STATES OF AMERICA as
represented by the Secretary United
States Department of Commerce te
Springfield, Virginia 22161, Verenigde
Staten van Amerika (US).
990038
NORSK PATENTTIDENDE

APPENDIX 18

NO

Meddelt supplerende beskyttelsessertifikater

Søknad nr. | Basis patent nr. | søker | Produkt | Oppfølgingens besteutvalg
--- | --- | --- | --- | ---
SPC/NO 1998002 | 170284 | Bristol-Myers Squibb Co | Etoposid-ferumnet | Antikoagulans av betydelig effekt, som g. a. har en tertbutyloxykohlenstoffverbundene vätska.
14/01/1998 | | P. O. Box 5100 | 12.04.2011 | 951139
| | Wallingford, CT 06492-7860, US | 23.10.1997 | SE 112512
| | Dag Davies - Bryn & Aarflot AS | 0104 Oslo | 12.04.1996

SPC/NO 1999005 | 180447 | Merck Sharp & Dohme Ltd | Rizopteran | Imidazol-, triazol- og tetrazoldervantar. Fornøyelsesfylde preparater inneholdende dosis og anvendelse av forbindelsene for fremstilling av medikamenter.
09/04/1999 | | Hertford Road | 11.02.2013 | NL 21815-16
| | Landbergs Patentkontor AS | 0006 Oslo

SPC/NO 1999024 | 301585 | Dr. Karl Thoma GmbH | Telmisartan | Benzenimidazole og legemidler inneholdende dosis.
| | Johan H. Garbats - Bryn & Aarflot AS | 0104 Oslo

Tilbaketatte, avslatte eller henlagte patentsøknader som er allment tilgjengelige

| 19931523 | 19931995 | 19933209 | 19934402 | 19941973 | 19942313 | 19942920 | 19943399 | 19943534 | 19943726
| 19952234 | 19952243 | 19952848 | 19953921 | 19960215 | 19963248 | 19964263 | 19964812 | 19964870 | 19971382
| 19971761 | 19974909 | 19975951

Date: January 2002
### Innleggelse mot patent

<table>
<thead>
<tr>
<th>SPC nummer</th>
<th>Patent nr</th>
<th>Patent ansønd nr</th>
<th>Innlegger</th>
<th>Datum for innlegging</th>
<th>Kartlegging av mottatt patent</th>
<th>Fulltekst for innleggeren</th>
</tr>
</thead>
<tbody>
<tr>
<td>C 12 P 23 00 A 23 K 138</td>
<td>365 762 1988 556</td>
<td>(73) Get-Brocades NV, Peethoven 1, NL-2000 MA Delft, NL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Nye søknader om supplerende beskyttelsessertifikater

<table>
<thead>
<tr>
<th>Søknad nr</th>
<th>Langavseelsdag</th>
<th>Basis patent nr</th>
<th>Sokter</th>
<th>Produkt</th>
<th>Oppfyllelsens bemerkelse</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPC/NO 2000001</td>
<td>13.04.00</td>
<td>177 032</td>
<td>Merck &amp; Co Inc, 120 East Lincoln Avenue, Nutley, NJ 07110, US</td>
<td>Tredjehan, eventuelt i form av ei (farmaceutisk) skapartebelalt salt, forhenværende hydroklorid</td>
<td>Analog/fremgangsmåte for fremstilling av terapeutisk aktive forbindelser</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

[Appendix 19 follows]
## APPENDIX 19

### Certificados complementares de proteção

#### Menções de concessão

**Pedidos**

A publicação dos pedidos de certificados complementares de proteção a seguir indicados é feita nos termos dos Regulamentos (CE) do Conselho n° 1768/92, de 18 de Julho, e 1610/95, de 23 de Julho.

<table>
<thead>
<tr>
<th>Processo</th>
<th>Tipo de dado</th>
<th>Conteúdo do dado</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>55 S</td>
<td>Data da concessão</td>
<td>88261 G de 1988.08.12.</td>
<td>23 de Julho 1988</td>
</tr>
<tr>
<td></td>
<td>Nome do invento</td>
<td>H. L. Morgan</td>
<td>1988.08.12.</td>
</tr>
</tbody>
</table>

[Appendix 20 follows]
APPENDIX 20

PRV
PATENT- OCH REGISTERINGSVERKET

The Swedish certificate

EG-FÖRORDNINGEN 1768/92

BEVIS OM TILLÄGGSSKYDD 9990029-2
Meddelat 1999-12-20

I enlighet med artikel 10.1 i ovanstående förordning meddelas tilläggsskydd på produkten Becaplermin (rekombinant human blodplättshärledd tillväxtfaktor-BB, rh PDGF-BB).

Produkten skyddas av grundpatentet EP 85112852.0 (0177957)

Innehavare av tilläggsskyddet

ZymoGenetics, Inc

Tilläggsskyddet inträder from 2005-10-11
och kan upprätthållas t.o.m 2010-10-10

För varje påbörjat avgiftsår skall en årsavgift betalas för tilläggsskyddet.
Första årsavgiften förfaller till betalning 2005-10-31

I tjänsten

Gerd Strandell
Ansökan om tilläggsskydd för läkemedel

A61K 31/165 ——> (51) C07C 311/02
A61K 31/395 ——> (51) C07C 311/02
C07C 211/45 ——> (51) C07C 311/02
C07C 215/42 ——> (51) C07C 311/02
C07C 217/64 ——> (51) C07C 311/02
C07C 233/64 ——> (51) C07C 311/02
C07C 237/28 ——> (51) C07C 311/02

(51) C07C 311/02 (21) 0090007-6 L
C07C 311/15 C07C 317/14
C07D 295/18 C07C 233/64
C07C 237/28 C07C 215/42
C07C 217/64 C07C 211/45
A61K 31/165 A61K 31/395

(21) 87303782.4 (11) 0 245 997
(92) 1999-11-29 EG EU/1/99/121/001
(93) 1999-11-29 EG EU/1/99/121/001

(95) Dofetilide, eventuellt i form av ett farmaceutiskt föredraget salt
(54) N-substituerade P-aminoetylsulfonanilider som antiarytmika samt mellanprodukter för dessa
(71) Pfizer Limited, Sandwich Kent CT13 9NJ,

C07C 311/15 ——> (51) C07C 311/02
C07C 317/14 ——> (51) C07C 311/02
C07D 295/18 ——> (51) C07C 311/02

[Appendix 21 follows]
and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:
Claudia V. Grillo, Regulatory Policy Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 103-424) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item is a human drug product, animal drug product, medical device, food additive, or color additive) subject to regulatory review by FDA before the item was marketed. Under these acts, a product’s regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the extension permit the clinical trials of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was ‘sued), FDA’s determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(2)(B).

FDA recently approved for marketing the human drug product ‘Zagler™ (abacavir). Zagler™ is indicated for the treatment of HIV-1 infection. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for Zagler™ (U.S. Patent No. 5,034,394) from ‘Zagler Wellness, Inc. and the Patent and Trademark Office requested FDA’s assistance in determining this patent’s eligibility for Patent Term Restoration. In a letter dated May 10, 1999, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of Zagler™ represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product’s regulatory review period.

FDA has determined that the applicable regulatory review period for Zagler™ is 1,852 days. Of this time, 1,855 days occurred during the testing phase of the regulatory review period, while 177 days occurred during the approval phase. These periods of time were derived from the following dates:
1. The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective: July 1, 1994. The applicant claims June 21, 1994, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was July 1, 1994, which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to the human drug product under section 505 of the act: June 24, 1998. FDA has verified the applicant’s claim that the new drug application (NDA) for Zagler™ (NDA 20-977) was initially submitted on June 24, 1998.
3. The date the application was approved: December 17, 1998. FDA has verified the applicant’s claim that NDA 20-977 was approved on December 17, 1998.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 906 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before March 25, 2000, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before July 25, 2000, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Date: December 23, 1999.

Jane A. Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research.

(Doc. 00-1871 Filed 1-26-00; 8:45 am)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 98E-0853]

Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGen®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for GlucaGen® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Submit written comments and petitions to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) is subject to regulatory review by FDA before the item was marketed. Under these acts, a product’s regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug
Federal Register / Vol. 65, No. 18 / Thursday, January 27, 2000 / Notices 4433

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for SensoMed, Inc.'s product, the trigger electrode. Although only a portion of the regulatory review period is being published, this notice provides the date of approval and the dates of the pertinent events that comprise the regulatory review period, as required by law. FDA is publishing this notice of that determination as required by law. FDA published the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.

ADDRESS: Submit written comments and petitions to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy Staff (HFD-100), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For medical devices, the testing phase begins with a clinical investigation of the device and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the drug and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (half the testing phase may be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a medical device will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(b)(3)(B).

FDA recently approved for marketing the human drug product Glucagel® (glucagon [DNA origin]). Glucagel® is indicated for the treatment of hypoglycemia. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for Glucagel® (U.S. Patent No. 4,826,763) from Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated May 27, 1999, FDA advised the Patent and Trademark Office that the human drug product had undergone a regulatory review period and that the approval of Glucagel® represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for Glucagel® is 2,296 days. Of this time, 2,296 days occurred during the testing phase of the regulatory review period, while 77 days occurred during the approval phase. Those periods of time were derived from the following dates:

2. The date the application was initially submitted with respect to the human drug product under section 505 of the act: September 23, 1997.
3. The date the new drug application (NDA) for Glucagel® (NDA 20–918) was initially submitted. However, FDA records indicate that NDA 20–918 was submitted on September 23, 1997.

For purposes of the act, the time period between the date of the new drug application (NDA) and the date that the NDA application is approved is considered the regulatory review period. Therefore, the application was approved on June 22, 1999. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,423 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before March 21, 2000, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before July 25, 2000, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. [See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.] Petitions should be in the format specified in 21 CFR 10.30. Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Jane A. Axelrod,
Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 00–1872 Filed 1–28–00; 8:45 am]
BILLING CODE 4180–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

[Docket No. 99–D–0119]

Determination of Regulatory Review Period for Purposes of Patent Extension; Sentinel Model 2000/2010®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

en / 07-07-01 Date: January 2002

Certificates extending the terms of the following patents were issued on April 24, 1992.

U.S. Patent No. Re. 30,577; Reissued April 14, 1981, to Norbert Busch et al.; Owner of Record: Rim Laboratories Inc.; Class: ETHER OF N-PROPAHOL AMINE; Classification: 548/569; Product Trade Name: Bepadin/Vascor; Term Extended: Two years.

U.S. Patent No. Re. 32,969; Reissued June 27, 1989 to Seymour F. Trager et al.; Owner of Record: Inventors, Title: INJECTIONABLE VISCOELASTIC OPHTHALMIC COMPOUND; Classification: 424/81; Product Trade Name: Oftocon; Term Extended: 931 days.

U.S. Patent No. 4,337,201; Granted June 29, 1982, to Edward W. Petrillo, Jr.; Owner of Record: E. R. Squibb & Sons, Inc.; Title: PHOSPHINYLALKANOYL SUBSTITUTED PROLINE; Classification: 548/413; Product Trade Name: Monopril; Term Extended: Two years.

U.S. Patent No. 4,410,520; Granted: Oct. 18, 1983, to Jeffrey W. H. Wathney; Owner of Record: Ciba-Geigy Corp.; Title: 3-AMINO-[1]-BENZAZEPIN-2-ONE-1-ALKANOIC ACIDS; Classification: 514/212; Product Trade Name: Louensin; Term Extended: Two years.

U.S. Patent No. 4,701,460; Granted: Oct. 20, 1987, to Hassan A. El-Sayed et al.; Owner of Record: Burroughs Wellcome Co.; Title: LONG DURATION NEUROMUSCULAR BLOCKING AGENTS; Classification: 514/308; Product Trade Name: Nuromax; Term Extended: 137 days.
UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

PATENT NO.: 3,998,790
DATED: December 21, 1976
INVENTORS: Arne Elof Brandstrom et al.
PATENT OWNER: Aktiebolaget Hassle

This is to certify that there has been presented to the
COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that
the requirements of the law have been met, this certificate extends the term of the patent for the
period of

2 YEARS

with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).

I have caused the seal of the Patent and Trademark
Office to be affixed this 20th day of May 1993.

Michael K. Kirk
Acting Commissioner of Patents and Trademarks

[End of Appendix 21 and of Survey]